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Prostate cancer (PCa) is the second most diagnosed cancer in males. This disease 
disproportionately affects African American men, with a higher incidence and mortality 
compared to other ethnic/racial groups. An aging male population and the complexity of 
addressing the health disparities associated with this disease puts PCa into the spotlight 
due to its serious public health implications and the imminent fiscal challenge over the 
next decades. Chronic prostate inflammation resulting in activation of stress and pro-
survival pathways contribute to disease progression and the development of 
chemoresistance. Lens epithelium-derived growth factor p75 (LEDGF/p75) is a stress-
response protein that promotes cellular survival against environmental stressors, 
including oxidative stress, radiation, and cytotoxic drugs. It is overexpressed in PCa and 
other cancers and has been associated with features of tumor aggressiveness, including 
resistance to cell death and chemotherapy. This research work shows that the endogenous 
levels of LEDGF/p75 are upregulated in metastatic castration resistant prostate cancer 
(mCRPC) cells selected for resistance to the taxane drug docetaxel (DTX). These cells 
also showed resistance to the taxanes cabazitaxel (CBZ) and paclitaxel (PTX), but not to 
the classical inducer of apoptosis TRAIL. Silencing LEDGF/p75 effectively sensitized 
 xvii 
taxane-resistant PC3 and DU145 cells to DTX and CBZ, as evidenced by a significant 
decrease in their clonogenic potential. While TRAIL induced apoptotic blebbing, 
caspase-3 processing, and apoptotic LEDGF/p75 cleavage, which leads to its 
inactivation, in both taxane- resistant and -sensitive PC3 and DU145 cells, treatment with 
DTX and CBZ failed to robustly induce these signature apoptotic events. Also, pre-
treatment with caspase inhibitor zVAD partially rescued the cells from TRAIL-induced 
cell death. These observations suggested that taxanes induce both caspase-dependent and 
-independent cell death in mCRPC cells, and that maintaining the structural integrity of 
LEDGF/p75 is critical for its role in promoting drug-resistance. We also report the initial 
screening and selection of candidate small molecule inhibitors (SMIs) to target this 
protein and sensitize taxane-resistant cells to chemotherapy.  
 
 1 
CHAPTER ONE 
INTRODUCTION 
Prostate Cancer and Available Therapies 
Prostate cancer (PCa) accounts for 1 in 5 new cancer diagnoses in men in the 
United States, and is the most frequently diagnosed cancer in this population, with 
161,360 new cases and 26,730 deaths projected for 2017 [1]. Furthermore, it has been 
extensively documented that this malignancy disproportionately and aggressively affects 
African American men [2-3]. This group is more likely to be diagnosed with PCa, with 
an estimated 1 in 6 African American males being diagnosed over their lifetime 
compared to 1 in 8 Non-Hispanic white males. Also, they are more likely to be diagnosed 
at an advanced stage and present a lower-stage five-year relative survival, with a 2.4 
higher mortality rate compared to Non-Hispanic whites [2, 4]. Although they are the 
group most affected by this disease, African Americans are still underrepresented in 
potentially life-saving clinical trials [5]. An aging male population and the complexity of 
addressing PCa mortailty disparities puts this malignancy in the spotlight due to the 
serious public health and fiscal challenge it will pose over the next decades [2-6].   
Although PCa is treatable in its earlier stages, resistance to chemotherapeutic 
drugs is a major deterrent to effectively treat the advanced form of the disease, known as 
castration resistant prostate cancer (CRPC). Previously known as hormone-resistant 
prostate cancer, CRPC is characterized by disease progression despite of castrate levels 
of circulating testosterone [7]. Treatment options for CRPC include systemic 
chemotherapy with the taxanes docetaxel (DTX) and cabazitaxel (CBZ) [7-8].  
Taxanes prevent the disassembly of the microtubules [9].  These are essential 
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components of the cytoskeleton involved in many vital cellular functions such as 
chromosome separation, cell shape, vesicle transport, transcription factor trafficking, 
mitochondrial functioning, adaptation to the microenvironment, and cell signaling [9, 10]. 
Treatment with taxanes results in cell cycle arrest and cell death [9].  Paclitaxel (PTX) 
was the first taxane to become clinically available as a single-agent and is currently 
utilized for the treatment of ovarian, breast and non-small-cell lung cancers, as well as 
Kaposi’s sarcoma [11, 12]. It’s not widely utilized for the treatment of CRPC since the 
results of phase II clinical trials were modest and there were not phase III trials to test for 
the efficacy of this drug alone or in combination with another microtubule inhibiting 
agent, entramustine [11]. This taxane features a common tetracyclic baccatin core with a 
side chain at C13, a benzyl amide moiety at C3, a hydroxyl a C7 and an acetyloxy at C10 
[12].  The chemical structure of PTX is shown in Figure 1. 
Docetaxel (DTX) is a semisynthetic taxane that contains a benzyl amide moety in 
the position C3 substituting the bulky benzyl amide moiety, and that showed 
approximately twice the efficacy of PTX in pre-clinical models  (Figure 1) [11, 12]. The 
use of DTX (75 mg/m2 every 3 weeks) plus prednisone (10 mg/day) is the first-line 
therapy currently recommended by international guidelines for patients with symptomatic 
CRPC [13]. In a randomized trial, TAX 327, treatment with DTX showed an average 
overall survival (OS) of 18.9 months compared to the group treated with the drug 
mitoxantrone which showed an OS of 16.5 months [13, 14]. Although DTX is 
extensively utilized as the first-line chemotherapy treatment for CRPC, there are still 
concerns about the variable response in patients, initial resistance to the drug, and serious 
adverse effect [15].  
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Cabazitaxel (CBZ) is a dimethyloxy derivative of docetaxel (Figure 1) with less 
affinity to the multi-drug resistance protein P-glycoprotein and with an increased 
penetration potential of the blood-brain barrier in preclinical models [16].  Like PTX, 
both DTX and CTX have a common tetracyclic baccatin core structure with a side chain 
at C13, but differ at C7 and C10 since the hydroxyl groups in DTX are substituted by 
acetoxy groups in CBZ (Figure 1) [12].  In the TROPIC clinical trial, CBZ (25 mg/m2) 
plus prednisone (10 mg/day), showed benefits in patients compared to the group treated 
with mitroxantone with OS of 15.1 and 12.7 months, respectively [17].  Before the 
approval of CBZ by the FDA in 2010, second-line treatment options after development of 
resistance to DTX were limited to palliative care with little OS benefit [16].  
It is also important to consider the role of androgen receptor (AR) activation in 
the development of advanced disease even after progression to CRPC.  Mechanisms 
including increased AR synthesis, mutation and splice variants, overexpression and its 
co-activators, and crosstalk between AR signaling and other signal transduction pathways 
such as glucocorticoid signaling can increase AR activation with marginal levels of 
androgens, thus representing a promising treatment strategy for advanced disease [17]. 
Androgen deprivation therapies (ADT) with enzalutamide or abiraterone acetate plus 
prednisone, and other non-ADT therapies such as sipuleucel-T and radium-223, are now 
available to patients with CRPC, with average overall increase in survival of 3-5 months 
and improvement in relevant secondary end-points (Figure 2) [14]. Unfortunately, CRPC 
is still poorly managed and most patients succumb to the disease within 3 years of 
diagnosis [14, 15]. Development of primary resistance and cross-resistance are not 
uncommon, [7, 15] and exposure to ADT itself may lead to metastatic disease [15].   
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Figure 1. Chemical structure of PTX, DTX and CBZ. These taxanes have a common 
tetracyclic baccatin core with a side chain at C13, but have functional group 
modifications three sites.  (Adapted from Churchill et al, 2015) [12]. 
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Figure 2. Currently available treatment options for CRPC (adapted from Fujimoto et al, 
2016) [17].   
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Inflammation and Prostate Cancer 
A recent study linked the role of chronic inflammation in benign prostate tissue 
with increased odds of developing high grade PCa compared to those patients with no 
histological evidence of inflammation [18]. Growing evidence suggests that inflammation 
plays a role in the regulation of the tumor microenvironment and the disruption of the 
anti-tumor immune response, leading to the development of PCa [19, 20].  Also, DNA 
damage may result from inflammation-induced oxidative stress leading to gene re-
arrangements and other anomalies associated with aggressive disease [21]. Thus, the 
identification of proteins involved in resistance to inflammation-induced oxidative stress 
is not only critical to understand the molecular pathogenesis of PCa, but also to develop 
individualized treatment strategies to improve prognosis in CRPC patients [22]. 
 
The Lens Epithelium-Derived Growth Factor of 75kD 
 Lens Epithelium Derived Growth Factor of 75 kD (LEDGF/p75) has recently 
emerged as a stress protein that promotes cellular survival against many different 
environmental stressors, including oxidative stress, radiation, heat, serum starvation, and 
cytotoxic drugs such as DTX, particularly in cancer cells [23-35].  Also known as PC4 
and SFRS1 interacting protein (PSIP1), and dense fine speckled autoantigen of 70 kD 
(DFS70), this protein has recently attracted considerable attention due to its broad 
relevance to cancer, autoimmunity, eye diseases, and HIV-AIDS [29, 30]. LEDGF/p75 is 
the target of autoantibody responses in a subset of patients with PCa, as well as in 
patients with diverse chronic inflammatory conditions and some apparently healthy 
individuals [29, 36-37].  While early studies suggested that LEDGF/p75 was a growth 
factor critical for the proliferation of lens epithelial cells [23], subsequent studies have 
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demonstrated that this protein is not a lens specific growth factor but rather a ubiquitous 
nuclear transcription co-activator with oncogenic functions that is activated during the 
cellular response to stress [29, 30].  Over the past decade LEDGF/p75 has also emerged 
as a critical cellular factor for the integration of the human immunodeficiency virus 1 
(HIV-1) [38-43]. Through interaction with the HIV integrase (HIV-IN), LEDGF/p75 
facilitates the integration of HIV-1 into host chromatin [44]. 
 
LEDGF Structure and Function 
The PSIP1 gene has been mapped to chromosome 9p22.2 and encodes various 
splice variants of LEDGF [23], but the two more commonly recognized are LEDGF/p75 
and its short alternative spliced variant LEDGF/p52 (Figure 3) [29].  Both LEDGF splice 
variants belong to the hepatoma derived growth factor (HDGF) family [26, 45], with a 
characteristic highly conserved PWWP domain, defined by the presence of the proline-
tryptophan-tryptophan-proline amino acid sequence motif. The PSIP1/LEDGF gene is 
constituted by 15 exons and 14 introns, with exons 1-15 (530 amino acids) encoding 
LEDGF/p75 and exons 1–9 and 24 nucleotides of intron 9 encoding LEDGF/p52 (333 
amino acids). The intron-derived carboxyl (C)-terminal tail-terminal tail (CTT, amino 
acid residues 326-333) is uniquely present in LEDGF/p52 but not in LEDGFp75. 
Although the function of this unique CTT is not completely clear, previous studies from 
our group implicated it in the pro-apoptotic function of LEDGF/p52, which, unlike 
LEDGF/p75, does not appear to have cellular survival functions [63].  Both splice 
variants of the PSIP1/LEDGF gene share the amino (N)-terminal residues 1-325, where 
the PWWP domain is located (residues 1-98) [23, 26, 45-46]. 
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Figure 3. Representation of the two main splice variants of LEDGF, p75 and p52 
(adapted from Ochs et al, 2016) [29].  
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The PWWP domain is a highly conserved region in members of the hepatoma 
derived growth factor (HDGF) family and is functionally relevant to both splice variants 
since evidence suggest its role in DNA binding, transcriptional repression, and 
methylation [26, 45-47].  This domain facilitates the chromatin recognition, dynamic 
interaction, and locking of LEDGF/p75 when this protein has interacting proteins bound 
to its C-terminus [48].  In addition, the PWWP domain of LEDGF/p75 specifically 
recognizes trimethylated histone H3K36, suggesting binding of this protein to 
transcriptionally active regions in the chromatin [49]. Solution structure analysis of the 
LEDGF/p75 PWWP domain revealed two distinct functional interfaces: a hydrophobic 
cavity that interacts with the histone H3 tail containing trimethylated Lys36 (H3K36me3) 
as well as a basic surface that binds non-specifically to DNA [50].  This cooperative 
binding may be critical for high-affinity binding to chromatin since nucleosomal DNA 
enhanced the binding affinity by 10,000 fold [51].   
Other important structural features that are shared by the N-termini of 
LEDGF/p75 and LEDGF/p52 are three charged domains (CR1, CR2, CR3), a nuclear 
localization signal (NLS) (residues 148-156), a TAT- like sequence within the NLS, and 
a basic leucine zipper (zip) sequence that overlaps with a helix-turn-helix (HTH) region 
(residues 154-175) [28, 40, 52] (Figure 3).  This zip sequence also overlaps with two AT-
hooks (residues 178-183 and 191-197).  Functionally, AT-hooks bind to the minor 
groove of DNA rich in AT nucleotide sequences and evidence suggests that these might 
facilitate accessibility of promoters to transcription factor by modifying the architecture 
of DNA [49]. The tripartitite region, consisting of the NLS and AT-hooks are sufficient 
for chromatin binding [52]. The second charged region (CR2), also designated the 
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supercoiled DNA recognition domain (SRD; residues 200-336), allows LEDGF/p75 to 
preferentially bind to active transcription sites in the negatively supercoiled DNA over 
unconstrained DNA [53]. The region comprised of residues 137–206 has been termed as 
non-specific DNA-recognition domain (NRD) [53].   
The C-terminal region of LEDGF/p75 (residues 339-442), which is absent in 
LEDGF/p52, shares amino acid sequence homology with the HDGF-related protein 2 
(HRP-2) and has been identified as the HIV-1 IN binding domain (IBD) [40, 54].  The 
IBD overlaps almost entirely with the epitope recognized by human autoantibodies 
recognizing LEDGF/p75, which are produced by healthy individuals as well as patients 
with different inflammatory conditions and some patients with PCa [29, 55].  Both the N- 
and C-terminal regions of LEDGFp75 are necessary for its transcription and stress 
survival functions by engaging in interactions with chromatin- binding proteins, or by 
binding to promoters regions of specific stress genes [42, 56-61]. Secondary amino acid 
sequence structures in the C-terminus of LEDGF/p75 are in their majority large random 
coiled regions containing disordered regions, implicated in the recognition of DNA and 
RNA, modulation of protein binding, and regulation of protein lifetime [62]. In addition, 
PSIPRED protein structure prediction server V2.1 and PHDsec programs predicted a 
LEDGF/p75 secondary structure consisting of N-terminal β-strand and α-helix [26].  
The interaction of the LEDGF splice variants with multiple proteins or DNA to 
form an interactome suggests its significance in multiple processes that include 
proliferation, growth, differentiation, and cell survival and death [29]. There are studies 
reporting differences in the roles and interactions of LEDGF splice variants depending on 
the cellular context.  For example, the two isoforms interact differently with proteins 
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involved in mRNA processing such as the Serine/arginine-rich splicing factor 1 (SRSF1) 
[49]. Our group also reported the antagonistic roles of LEDGF/p75 and LEDGF/p52 in 
the context of cell death [63]. During caspase-dependent cell death, p52 is cleaved by 
caspase-3 into fragments p48 and p38.  Particularly, p38 lacks the PWWP domain at the 
N-terminus and is unable to transactivate the promoter (pr) region of heat shock protein 
27  (HSP27), a well-known target gene of LEDGF/p75 [63] (Figure 4A). This cleavage 
fragment is however able to repress the HSP27pr transactivation potential of LEDGF/p75 
and retains some of its chromatin association abilities.  Interestingly, apoptosis can be 
induced when either p52 or its variants lacking most of the PWWP domain are 
overexpressed in tumor cell lines [63]. Our group also showed that cleavage of 
LEDGF/p75 during apoptosis by caspases-3 and -7 into a prominent fragment of 65 kD 
not only abrogated its pro-survival functions but also accelerated cell death under 
starvation conditions (Figure 4B) [26].   
There is evidence suggesting that there are other genetic variants of LEDGF/p75 
different from LEDGF/p52.  Some of these have been identified in leukemic cells and 
thougth to play different roles in apoptosis and cell survival [32].  Other variants derived 
from gene polymorphisms may affect the outcomes and pathogenesis of HIV-1 [64].  For 
instance, a study revealed that two LEDGF/p75 exonic variants, I436S and T473I were 
identified from a cohort of HIV-1 long-term nonprogessor patients [65]. However, further 
characterization revealed that these variants did not alter the interaction of LEDGF/p75 
with HIV-1 IN [65]. 
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Figure 4. Caspase mediated cleavage of LEDGF/p52 (A) and LEDGF/p75 (B) during 
apoptosis.  (Adapted from Brown et al, 2008 and Wu et al, 2002) [26, 63].    
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Cellular Protective and Survival Functions of LEDGF/p75 
Multiple studies have demonstrated the cellular protective functions of 
LEDGF/p75 upregulation against cellular stress inducers that may lead to an augmented 
state of oxidative stress, such as ultraviolet B (UVB) irradiation, hydrogen peroxide, 
alcohol, hyperthermia, nutrient deprivation, and some chemotherapeutic drugs [25-28, 
32-35, 66-69]. LEDGF/p75 is a transcription factor adaptor with chaperone and 
chromosome-docking properties [48, 70], and evidence suggests that this protein aids in 
the transcription and activation of stress, antioxidant, and other protective and stress-
survival genes [27, 71-79]. 
LEDGF/p75 is emerging as an important player in carcinogenesis as cells 
upregulate this stress-induced protein to evade cell death, induce favorable growth 
signals, and upregulate oncogenic proteins to maintain pro-survival functions such as 
cellular repair, protection from DNA damage, lysosomal stability, proteolytic evasion, 
and angiogenesis [33-34, 71, 77, 80]. Upon cellular exposure to a damaging agent that 
induces oxidative or thermal stress, LEDGF/p75 is upregulated and binds to heat shock 
elements (HSE) and stress response elements (STRE) in the promoter regions of specific 
target genes [27]. This transcription co-activator enhances the transactivation of 
antioxidant genes like albumin (ALB), thyroid peroxidase (TPO), superoxide dismutase 3 
(SOD3), cytoglobin (CYGB), and antioxidant protein 2/peroxiredoxin 6 (AOP2/PRDX6), 
thus reducing the oxidative damage caused by oxidative stress and helping cells (both 
normal and cancer) evade cell death [79, 81].  In addition, LEDGF/p75 enhances the 
transactivation of anti-apoptotic proteins HSP27 and αB-crystallin that respond to stress-
related damage by inhibiting caspase-3 activation [27, 82-83]. LEDGF/p75 also 
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transactivates the vascular endothelial growth factor C (VEGF-C), a prosurvival protein 
involved in angiogenesis and cancer metastasis [77, 84].  
Several studies have also linked LEDGF/p75 aberrant expression to human 
leukemogenesis [85]. LEDGF/p75 expression was upregulated in chemoresistant blasts 
obtained from acute myeloid leukemia (AML) patients [32]. In addition, a chromosomal 
translocation associated to leukemogenesis, t(9;11)(p22;p15), results in a fusion of the N-
terminal part of the nucleoporin 98 protein (NUP98) to the C-terminus of LEDGF/p75 
[86-91]. LEDGF/p75 has also been identified as a key co-factor of the mixed lineage 
leukemia (MLL)–fusion complexes [85]. Specifically, the interaction of LEDGF/p75-
NUP98 with menin-MLL complexes in leukemic cells targets the homeobox HOX genes 
that are normally associated with stem cell self-renewal, a function exploited by 
migrating cancer progenitors [59, 92]. The role of LEDGF/p75 in leukemia is discussed 
in more detail below. 
 
Target Genes of LEDGF/p75 
Detailed studies of LEDGF/p75 target genes are necessary to further understand 
its protective and cellular functions. Although it was initially reported that LEDGF/p75 
interact with the HSE and STRE in promoter regions of its target genes [27, 61], further 
studies from our group and others failed to confirm these findings [52, 82]. Recently, 
studies using the DamID technology focusing on the highly annotated ENCODE 
(encyclopedia of DNA elements) region, demonstrated that LEDGF/p75 binds to DNA 
primarily downstream of the active transcription unit start sites. This binding is not 
restricted to STREs, and correlates with active chromatin markers and RNA polymerase 
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II binding [93]. We have to consider the possibility that LEDGF/p75 interacts with a 
particular motif in a promoter region depending on the cellular microenvironment and/or 
stress conditions. For instance, LEDGF/p75 might interact with a particular promoter 
element (such as STRE) of a certain target gene, for example HSP27, in a particular 
cellular system under conditions of stress such as drug treatment [82]. This would explain 
the differences observed in these previous studies, since not all were conducted under 
conditions of stress.   
It remains to be established if the binding of LEDGF/p75 to specific promoter 
elements in its target genes occurs in different cellular contexts (e.g. cancer vs non-
cancer, stress vs non-stress, microenvironment). As mentioned above, various studies 
have identified several target genes of LEDGF/p75, including HSP27 [27, 82], αB-
crystallin [27, 76], gamma-glutamylcysteine synthetase [68], AOP2/PRDX6 [71], 
involucrin [72], alcohol and aldehyde dehydrogenases [75], VEGF-C [77-78], and 
interleukin 6 (IL-6) [94-95].   It is not clear, however, what are the specific 
microenvironmental, cellular, and molecular contexts that determine how and when 
LEDGF/p75 transactivates each one of these genes.   
 To identify additional target genes regulated by LEDGF/p75, our group utilized 
pathway specific gene expression profiling analysis in PC3 prostate cancer cells 
transiently depleted of this protein or stably overexpressing it [79]. Our study identified 
five oxidative-stress genes that exhibited statistically significant mRNA down- and up-
regulation (fold-change ≥ 2) in response to LEDGF/p75 knockdown and overexpression, 
respectively. These were: CYGB, phosphoinositide-binding protein (PIP3-E/IPCEF-1), 
SOD3, TPO, and ALB.  From this group, CYGB was selected for further validation and 
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characterization by immunoblotting due to its significance as a tumor suppressor gene, 
depending on context, and emergence as a cancer-associated stress protein [96-98]. Our 
results showed that LEDGF/p75 mRNA and protein expression in PCa cells paralleled 
those of CYGB [79]. Interestingly, our findings have been corroborated by a report that 
validated the elevated levels of CYGB protein in prostatic atrophy as compared to benign 
non-atrophic epithelium, prostatic intraepithelial neoplasia (PIN) or cancer [99]. This 
report proposed that CYGB has a protective function in preventing DNA damage induced 
by reactive oxygen species (ROS), aiding in the progression from inflammatory atrophy 
lesions to invasive carcinoma.  
 Other studies revealed that in leukemic cells LEDGF/p75 also regulates the 
expression of some HOX gene family members [59, 100]. It is plausible that gene 
regulation by LEDGF/p75 is dependent on cell type, stressor type and the 
microenvironment, as previously observed.   
 
Interacting Partners of LEDGF/p75  
LEDGF/p75 interacts with specific transcription factors to facilitate the 
transactivation of stress and cancer-related genes through both its PWWP domain and the 
C-terminal IBD region. Through its IBD region, LEDGF/p75 binds to and tethers MYC-
binding protein JPO2 to chromatin, hinting a plausible role in the MYC-regulatory 
network, important in human cancers [42, 46, 57, 60]. As a result of ROS accumulation 
in the cell, LEDGF/p75 interacts with transcription factors such as JPO2 and PC4 
transcription factor, pogo transposable element-derived protein with zinc finger (PogZ) 
[56], and cdc7 activator of S-phase kinase (ASK) [58].  These complexes then interact 
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with the promoter sites of antioxidant, anti-apoptotic, and other prosurvival genes. In 
leukemia cells, LEDGF/p75 interacts with the menin/MLL-HMT (mixed linkage 
leukemia-histone methyltransferase) transcription complex to transactivate cancer-
associated genes and facilitate leukemic transformation [59].  
The PWWP domain has been implicated by our group in the binding of MeCP2 
(methyl CpG binding protein 2) to both LEDGF/p75 and LEDGF/p52 [82]. This 
interaction occurs via the PWWP-CR1 domain found in the N-terminal region of 
LEDGF/p75 and differentially regulates the HSP27 promoter in cancer cells [82].  Other 
proteins that interact with LEDGF/p75 through the PWWP domain are the transcription 
activator TOX4 and the splicing co-factor NOVA [101]. In addition, LEDGFp75 also 
assists in the recruitment of polycomb group protein Bmi1 and co-repressor Ctbp1 to 
MLL complexes in the HOX gene promoters [102]. 
 
Regulation of LEDGF/p75 Expression and Function 
Studies were undertaken to find regulatory regions within the LEDGF/p75 
promoter, using promoter truncations in reporter assays. These concluded that 
LEDGF/p75 TATA-Less promoter activation is driven by the transcription factor Sp1 
since its increased expression leads to LEDGF/p75 upregulation, while its inhibition 
represses this upregulation [61, 103]. Regulation of LEDGF/p75 may involve 
posttranslational modifications by the small ubiquitin-like modifier 1 (SUMO1), with 
SUMOylation and deSUMOylation acting as a molecular switch that regulates the DNA-
binding and transactivation capacity of LEDGF/p75 [104-105].  In a study using lens 
epithelium cells exposed to UVB, Sp1 binding was disrupted by a histone 
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deacetylase/histone methylase (HDAC1/ SUV39H1) complex recruited to the Sp1 
regulatory region in the LEDGF/p75 promoter. This resulted in repression of LEDGF/p75 
expression, leading to cell stress and death [106].  
The transcriptional activities of LEDGF/p75 are also abrogated by the binding of 
transforming growth factor-β1 (TGF-β1) to its promoter region in lens cells [74]. This 
observation was consistent with studies using Prdx6-/- knockout mouse cells in which 
increased levels of TGF-β1 resulted in decreased LEDGFp75 expression [88]. This 
inverse relationship was also observed by Kubo and colleagues in diabetic and 
galactosemic cataractous rat lenses [107].  
The pro-survival protein B-cell leukemia/lymphoma protein 2 (Bcl-2) was 
reported to significantly downregulate the expression of endogenous αB-crystallin gene 
by decreasing the transcriptional and DNA binding activity of LEDGF/p75 [108]. In a 
separate study, the same group showed that Bcl-2 activates the ERK signaling pathway to 
downregulate LEDGF/p75 transcriptional activity, resulting in reduced expression of αB-
crystallin [109]. Kubo and colleagues corroborated this negative relationship between 
LEDGF/p75 and the TGF-β and Bcl-2 proteins in their gene microarray analysis [107]. 
  Evidence from our group also suggests that caspase-dependent apoptotic cell 
death appears to play a role in the regulation of LEDGF/p75 pro-survival functions. As 
shown above in Figure 4, during apoptosis caspase-3 cleaves LEDGF/p75 at specific 
aspartic acid residues located in the N-terminal PWWP domain and the C-terminal region 
into prominent fragments of 65 and 58 kD [26, 35, 63]. This apoptotic cleavage impairs 
the protein’s stress survival activity, resulting in increased cell death. The pro-survival 
functions of LEDGF/p75 are also negatively regulated by the alternative splicing of the 
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PSIP1/LEDGF gene, since p52 antagonizes its transcriptional activity and induces 
apoptosis in cancer cells [63]. As mentioned previously, our group observed that during 
apoptosis p52 is also cleaved by caspase-3 to generate a p38 fragment that antagonizes 
the transcriptional function of LEDGF/p75 [63]. Ectopic overexpression of LEDGF/p52 
resulted in decreased cell viability as a result of caspase-dependent cell death that 
resulted in LEDGF/p75 cleavage [63].  
 LEDGF/p75 transcription is also regulated by micro-RNAs (miRNAs). In one 
study miR-155 was induced in macrophages stimulated with lipopolysaccharide, resulting 
in down-regulation of LEDGF/p75, and ectopic expression of this miRNA reduced 
LEDGF/p75 transcript [110].  In a separate study it was demonstrated that miR-135b also 
down-regulated LEDGF/p75 both in human cell lines and in murine vestibular sensory 
epithelia of the inner ear [111].  
The PWWP domain was reported to also interact with partners possibly regulating 
its interaction with chromatin [101]. Thirteen potential partners were originally identified 
using yeast-two-hybrid, but TOX4 and NOVA1 were selected for further studies. Both 
proteins have DNA and RNA binding properties and are involved in transcriptional 
regulation [101]. TOX4 and NOVA1 co-localized with LEDGF/p75 in different cell 
lines. Three PWWP interacting regions (PIRs) of TOX4 and NOVA1 proteins were 
found to interact with the PWWP domain of LEDGF/p75. They also observed a reduction 
vesicular stomatitis virus G protein (VSV-G) pseudotyped HIV infection in cells 
transiently expressing Flag-tagged PIRs of TOX4 and NOVA1. This effect was possibly 
due to the inhibition of the LEDGF/p75 -IN interaction [101].  
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 Finally, the crosstalk between LEDGF/p75 and proteins involved in inflammation 
has been explored, suggesting a possible role of this protein in regulating inflammatory 
pathways, or, alternatively, these pathways regulating LEDGF/p75.  For instance, 
Takeichi and colleagues investigated the relationship between IL-6 and LEDGF/p75 in 
HaCaT cells [94, 95]. Their studies revealed that overexpression of LEDGF/p75 induced 
the MK2/IL-6/STAT3 (signal transducer and activator of transcription 3) signaling 
pathway via p38 phosphorylation, whereas its depletion reduced IL-6 levels. 
 Another study involving a microarray analysis after induction of STAT3β in 
breast cancer cells, which acting as a dominant-negative regulator promoted apoptosis, 
resulted in repressed LEDGF/p75 expression  [112].  Interestingly, overexpression of this 
survival protein rescued the cells from STAT3β’s effect on cell viability, suggesting a 
negative feedback mechanism  [112]. Numerous studies have suggested involvement of 
IL-6 and its receptor (IL-6R) in cellular/molecular events in which LEDGF/p75 is also 
involved such as drug resistance, anti-apoptotic effects, tumor progression, and 
development of CRPC under androgen deprivation [113-115].  These events also appear 
to be regulated through (STAT3) and Bcl-xl related pathways [116].    
 Future studies using RNA interference, chromatin immunoprecipitation (ChIP) 
analysis, transcription reporter assays, and electrophoretic mobility shift assays (EMSA) 
should be conducted to establish unambiguously whether IL-6 and other inflammatory 
cytokines are target genes of LEDGF/p75. 
 
Autoantibody Responses to LEDGF/p75 in Cancer and Inflammatory Conditions 
The presence of autoantibodies to LEDGF/p75 (referred to as the DFS70 
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autoantigen in the field of autoimmunity) in apparently healthy individuals and in a 
variety of inflammatory conditions has been thoroughly documented by our group and 
others [29, 30, 37]. The immune system responds to changes in the cellular 
microenvironment such as the up-regulation of tumor-associated antigens (TAAs), 
production of splice variants or cleaved fragments, and changes in the cellular 
concentration, distribution, localization, or excretion of specific endogenous proteins by 
producing antibodies to these autoantigens in genetically susceptible individuals [132].  
Up-regulation of LEDGF/p75 in response to chronic inflammation or malignant 
transformation is thought to lead to increased concentration, distribution, an aberrant 
immune presentation of this protein, consequently resulting in T cells recognizing this 
protein as abnormal and triggering B cells to produce an autoantibody response [132-
133].  This increased immunogenicity and autoantibody recognition of LEDGF/p75 has 
been reported in patients with certain inflammatory conditions such as atopic dermatitis, 
with cataracts and alopecia areata, as well as in PCa [36, 134-136]. Interestingly, 
LEDGF/p75 autoantibodies from patients with atopic dermatitis and cataracts were 
reported to be cytotoxic to the crystalline lens and lens epithelial cells [134].  
The clinical significance of LEDGF/p75 autoantibodies still remains unclear, 
since these antibodies have been identified in several autoimmune diseases at lower 
frequencies than sera from individuals with no evidence of autoimmune disease [137-
139].  This lower frequency of LEDGF/p75 autoantibodies in patients with systemic 
autoimmune rheumatic diseases (SARD) compared to apparently healthy individuals has 
recently led to the notion that anti-LEDGF/p75 autoantibodies could be utilized as 
biomarkers to rule out a SARD diagnosis [140].  
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In an early study, 597 self-reported healthy hospital workers were screened for the 
presence of antinuclear autoantibodies (ANAs) and observed that 54% of all ANA-
positive apparently healthy individuals had anti-LEDGF/p75 antibodies [139]. The 
conclusion was that this could be a naturally occurring autoantibody in both healthy and 
diseased individuals, not associated with a specific pathology. However, this was a self-
reporting study and the presence of an underlying disease could not be ruled out [29, 
141]. More recent studies have demonstrated that the anti-LEDGF/p75 antibody is 
detected both in apparently healthy individuals and patients with a variety of non-
rheumatic inflammatory conditions [37]. The increased frequency of LEDGF/p75 
autoantibodies in apparent healthy individuals does not necessarily rule out disease since 
the immune system in these individuals may recognize an aberrant expression of this 
protein that could be associated with an undiagnosed pathological condition.   
Our group previously reported that 22.3 % of PCa patients from a Loma Linda 
University cohort had circulating serum antibodies that reacted with LEDGF/p75 either 
by ELISA or immunoblotting, compared to 6.7 % of matched controls. The increase in 
the frequency of LEDGF/p75 autoantibodies in PCa patients is consistent with the 
elevated LEDGF/p75 expression in PCa tissues compared to normal adjacent tissue 
observed by our group [31, 36]. This observation of elevated frequencies of anti-
LEDGF/p75 autoantibodies was later independently confirmed by two other groups [142-
143], and is in agreement with the observation that altered LEDGF/p75 expression and 
function may contribute to tumor aggressive properties, which are discussed more 
extensively below [31-36, 59, 77-78, 83, 86-89, 120, 131, 144]. In a conflicting report, 
there were no detectable LEDGF/p75 autoantibodies in 40 cancer patient sera screened 
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by a chemiluminescence method, however, the cancer types were not disclosed [140]. We 
could speculate from all these studies that aberrant LEDGF/p75 overexpression, 
secretion, or cleavage during cell death might trigger autoantibodies under inflammatory 
conditions in certain genetically susceptible individuals.  
Autoantibody reactivity to tumor associated autoantigens such as p90, survivin, 
and p53 has been used in experimental studies to complement prostate specific antigen 
(PSA) testing, which is currently unable to effectively distinguish between inflammatory, 
benign, and malignant conditions of the prostate leading to a significant number of 
unnecessary biopsies [145-149]. The inclusion of LEDGF/p75 into panels of TAAs for 
serum autoantibody profiling improved the predictive frequency in patients with PCa 
compared to the PSA blood tests [142-143]. The inherent function of the immune system 
to recognize and report changes in the expression or structure of a normal cellular protein 
expression provides a window into early changes that could lead to a disease state.  This 
is leading to an increasing interest in TAAs and anti-TAA autoantibodies in cancer 
patients as potential diagnostic and prognostic tools, as well as reagents to develop novel 
immunotherapies [150]. 
 
Role of LEDGF/p75 in Leukemia 
The role of LEDGF/p75 in cancer was first hinted in various early studies 
revealing that chromosomal translocations may result in fusion proteins involving this 
protein, with potentially altered transcription function [86, 117]. This role has now been 
well documented in studies showing that a fusion between NUP98 gene (chromosomal 
location: 11p15.5) and LEDGF/p75 (chromosomal location: 9p22.3) results in a NUP98-
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LEDGF/p75 fusion gene with aberrant and malignant functions [86-91, 117-118]. The 
NUP98 gene encodes nucleoporin 98, a component of the nuclear pore complex that 
mediates nucleo-cytoplasmic transport of protein and mRNA [119]. It is involved in 
multiple rearrangements and fusions with more than 26 partner genes by translocations or 
inversions in hematological malignancies resulting in 5’-NUP98/3’-partner fusion genes 
[120-121]. The N-terminus of NUP98 contains Phe-Gly (FG) repeats that are known to 
interact with CREB binding protein (CBP) and its homologue p300, and act as oncogenic 
transactivation domains [122]. The NUP98-LEDGF/p75 fusion gene, likewise, involves 
the fusion of the C-terminus of LEDGF/p75 with the N-terminus of NUP98 caused by a 
rare but recurrent chromosomal translocation t(9;11)(p22;p15) that has been reported in 
four adult AML [86-87, 90, 117], one pediatric AML case [88], one chronic myeloid 
leukemia case [89], and one myelodysplastic syndrome (MDS) case [91]. All of the five 
AML cases reported with NUP98-LEDGF/p75 fusion are de novo, not related to therapy 
and have only t(9;11)(p22;p15) cytogenetic abnormality at diagnosis [90]. Among the 
seven reported cases of hematological malignancies with t(9;11)(p22;p15), only two were 
males, suggesting higher prevalence of NUP98-LEDGF/p75 fusion gene in females. This 
is consistent with reports of other NUP98 chimeras such as NUP98-HOXA and NUP98-
TOP1 being more common in women [120, 123]. It is evident from the mortality 
associated with the seven cases that NUP98-LEDGF/p75 fusion gene is a poor prognostic 
marker associated with leukemia and MDS [90-91].  
 Although the molecular mechanism of AML/CML/MDS with t(9;11)(p22;p15) 
fusions is still unclear, it has been speculated that NUP98 fusion genes induce a pre-
leukemic phase and that additional mutations in other cancer genes such as RAS are 
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required for progression to AML [91]. Available literature suggests different modes of 
action of NUP98 fusion with homeobox (eg. HOXA9, HOXD13) and non-homeobox (eg. 
TOP1, LEDGF/p75, DDX10) genes [124]. All the non-homeobox genes, including 
LEDGF/p75, were predicted to form “coiled-coils” which could lead to dimerization, 
oligomerization or the formation of multimeric complexes that enhance interaction with 
other transcription factors and co-factors [124].  It should be also noted that the NUP98-
LEDGF/p75 fusion removes the N-terminal region of LEDGF/p75, implicated in 
regulating the transcriptional activities of this protein [125], resulting in a LEDGF/p75 
variant with deregulated transcriptional activity and, consequently, increased pro-survival 
function in leukemic cells.   
There have been several other reports implicating LEDGF/p75 in leukemia. 
Identification of tumor-associated antigens in chronic lymphocytic leukemia (CLL) by 
SEREX (serologic identification by recombinant expression cloning) technique yielded 
an antigen that was identified as LEDGF/p75 [126]. Transcript expression of LEDGF/p75 
was also found to be upregulated in blasts from chemotherapy-resistant AML patients, 
and its ectopic overexpression protected leukemia cells against drug-induced apoptosis 
[32]. In a seminal study, Yokoyama and Cleary demonstrated that LEDGF/p75 tethers the 
menin-MLL transcription factor complex to chromatin to activate leukemogenesis [59]. 
This study also established LEDGF/p75 as a critical co-factor required for both 
promoting leukemic transformation and tumorigenic functions of MLL/menin complexes. 
Recently, Huang et al. analyzed the crystal structure of menin with an MLL protein 1 
(MLL1)-LEDGF/p75 heterodimer and concluded that menin assembles a menin-MLL1-
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LEDGF/p75 ternary complex to regulate gene transcription and promotes 
leukemogenesis [32].   
Another study assessing the anticancer potential of marine compounds derived 
from benthic cyanobacteria in AML cells concluded that strain M44 was highly 
promising since its activity induced apoptosis in chemoresistant AML cells with enforced 
expression of LEDGF/p75, thus counteracting the protective effects of this protein  [127]. 
The relevance of LEDGF/p75 in the development of leukemia has prompted researchers 
to explore targeting this protein as a therapeutic strategy [85, 128-130]. 
 
Overexpression and Role of LEDGF/p75 in Solid Tumors 
 Our group documented the upregulation of LEDGF/p75 in different cancer cell 
models compared to non-tumor cells, while its antagonistic alternative splice variant 
LEDGF/p52 is expressed at relatively low levels in cancer cells [26, 36, 63]. Our group 
was also the first to document the elevated LEDGF/p75 protein expression in clinical 
prostate tumor and benign prostatic hyperplasia tissues as compared to their 
corresponding normal tissues [36].  
 For several years, the only report of an immunohistochemical (IHC) LEDGF/p75 
protein expression analysis in human tumor tissues was the one performed by our group 
in PCa [36]. Other reports had only examined upregulation of LEDGF/p75 transcript 
expression in leukemia, breast, and bladder cancers [32, 34].  To establish the 
upregulation of LEDGF/p75 in cancer, our group published a comprehensive report on 
the mRNA and protein expression of LEDGF/p75 in 21 major human tumor types, using 
cancer gene microarray databases, TissueScan Cancer Q-PCR array, and 
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immunohistochemical (IHC) analysis of tissue microarrays (TMAs) comprising 1735 
tissue cores for this cross-platform analysis [31]. This study revealed selective 
LEDGF/p75 overexpression in human cancers, with statistically significant upregulation 
of both transcript and protein in prostate, colon, and thyroid malignancies. Bioinformatics 
analysis of PSIP1/LEDGFp75 transcript expression in the Oncomine database showed 
significant upregulation (tumor versus normal) in 15 of 17 tumor types. The TissueScan 
Cancer Q-PCR array revealed significantly elevated LEDGF/p75 mRNA expression 
(>1.5 fold) in 4 out of 8 tumor types, including prostate, colon, thyroid, and breast 
cancers. Significant overexpression of LEDGF/p75 protein was observed in prostate, 
colon, thyroid, liver and uterine tumors, relative to corresponding normal tissues when 
the IHC analysis was performed in TMAs.  This upregulation was associated with 
younger age in patients with liver and thyroid tumors [31].   
 The role of LEDGF/p75 as a candidate oncoprotein in cancer cells has been 
further corroborated by reports of its elevated transcript expression in human breast and 
bladder cancers, and the observation that its ectopic overexpression in breast cancer cells 
protected against drug-induced lysosomal cell death [34]. Consistent with this, our group 
demonstrated that overexpression of LEDGF/p75 in PCa cells attenuated lysosomal cell 
death induced by stressors that trigger oxidative stress such as the anti-tumor drug DTX 
[33]. LEDGF/p75 was also shown to enhance the tumorigenic potential of HeLa cancer 
cells in murine xenograft models [34]. In ovarian tumors, lymphangiogenesis and 
angiogenesis was observed as a result of increased LEDGF/p75-dependent activation of 
VEGF-C [78].  It was also reported that LEDGF/75 overexpression increased 
tumorigenic characteristics in metastatic DU145 prostate cancer cells since its depletion 
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impaired the proliferative and invasive ability of these cells [83]. Leitz and colleages 
[131] also demonstrated that LEDGF/p75 is overexpressed in human papilloma virus 
(HPV)-positive tumors and that downregulation of endogenous HPV18 E6/E7 gene 
expression repressed LEDGF/p75 expression in HeLa cells.  Transduciton of the HPV16 
E6, E7 or E6/E7 genes resulted in LEDGF/p75 promoter activation and increased gene 
expression. Importantly, LEDGF/p75 was shown to be crucial for the survival of HPV-
positive cancer cells after DNA damage by genotoxic agents [131].  
 
LEDGF/p75 Promotes Chemoresistance in Cancer Cells 
Despite the recent development of new chemotherapeutic drugs, many PCa 
patients eventually develop resistance to chemotherapy [15]. Several studies have 
implicated multiple mechanisms in the development of chemoresistance, such as the 
upregulation of pro-survival stress proteins, regulation of oxidative genes, induction of 
cytoprotective chaperones, and anti-apoptotic pathways [151].  Another important 
contributor to multi-drug resistance is increased expression of P-glycoprotein (P-gp), a 
member of the ABC superfamily of transporters.  P-gp expression is upregulated in an 
inherent or acquired process, leading to ATP-dependent drug translocation across the 
cellular membrane [152]. This decreases the concentration of drugs inside the cell 
contributing to multi-drug resistance [153]. Despite ongoing studies to understand 
mechanisms of chemoresistance, we are still elucidating these pathways with the purpose 
of better predicting drug response and effectively treating advance disease [151-152].  
 Various studies suggest that LEDGF/p75 is a potential therapeutic target to 
circumvent cancer chemoresistance [32-34, 36, 83, 144]. Increased expression of 
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LEDGF/p75 has been associated with increased tumorigenic properties and 
chemoresistance in various cancers.  For instance, Huang et al [32] reported increased 
mRNA levels of LEDGF/p75 in AML blast from patients that had developed 
chemoresistance. AML cells ectopically (plasmid-mediated) overexpressing LEDGF/p75 
showed a significant increase in survival compared to cells expressing the empty vector 
when both cell lines where treated with the anti-leukemic drug daunorubicin or cAMP 
analogs. These results suggested that increased expression of LEDGF/p75 contributes to 
chemoresistance in AML [32].  
Daugaard et al. [34] demostrated that Hsp70-2 is a regulator of LEDGF/p75 
expression in various cancer cell lines and that LEDGF/p75 knockdown with two 
different small inhibitory RNAs (siRNAs) resulted in increased caspase-independent cell 
death. The observed cell death was a result of lysosomal membrane permeabilization 
(LMP). Ectopic expression of LEDGF/p75 in MCF-7 cells resulted in protection against 
agents that increase LMP such as siramesine, etoposide, doxorubicin (DOXO), and TNF 
but not against the classical apoptotic-inducer staurosporine (STS) [34].  In a separate 
study, Daugaard et al. also reported that LEDGF/p75 is necessary for effective DNA 
double strand breaks repairs (DBSs) [144]. Osteosarcoma cells depleted of LEDGF/p75 
were unable to effectively repair DNA DBSs when they were exposed to DNA damaging 
agents such as the drugs camptothecin and mytomycin, or ionizing radiation, resulting in 
decreased cancer cell survival [144].  
The link between LEDGF/p75 overexpression in PCa and resistance to 
chemotherapy has also been explored in our laboratory. Our group demonstrated that the 
taxane drug DTX, the current FDA-approved standard of chemotherapy for the treatment 
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of advanced PCa, induces a caspase independent cell death through lysosomal 
destabilization and cathepsin B activation in PCa cells [33].  In that study, PC3 and 
RWPE-2 PCa cells with stable plasmid-mediated overexpression of LEDGF/p75 were 
found to be resistant to DTX as compared to cells transfected with an empty vector. 
These LEDGF/p75 overexpressing cells, when treated with DTX, exhibited stable 
lysosomes.  However, LEDGF/p75 overexpression did not abrogate DTX inhibition of 
microtubule depolymerization or cell death induced by TNF-related apoptosis inducing 
ligand (TRAIL), suggesting that LEGDF/p75 may be a selective inhibitor of cell death, 
protective against LMP but not against mitotic catastrophe or apoptotic cell death [33].  
Consistent with these results, we recently demonstrated that LEDGF/p75 
overexpression in PCa cells promoted protection against caspase-independent necrotic 
cell death induced by tert-butyl hydrogen peroxide (TBHP), a potent inducer of cellular 
oxidative stress, possibly through the upregulation of antioxidant pathways and protective 
proteins such as ERp57/GRP58 [35]. We also showed that PCa cells grown in the 
presence of DTX and selected for their resistance to this drug, have high endogenous 
levels of this protein compared to the parental, drug-sensitive cell lines [35, 81].  As 
described in the next chapter, the studies conducted for this dissertation demonstrated that 
these cells overexpressing LEDGF/p75 were not only resistant to DTX but also exhibited 
resistance to other taxane drugs used in clinical settings such as PTX and CBZ. 
 
Targeting LEDGF/p75 and its Potential in Combinatorial Therapy 
When a patient develops PCa, androgen deprivation therapy (ADT) is an effective 
but temporary treatment alternative until tumors continue to grow without the presence of 
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androgens. At this stage, systemic therapy with different rounds of the chemotherapeutic 
taxane drug DTX, and more recently CBZ, are the only alternatives available to increase 
patient survival [154]. Combinatorial therapies such as DTX with anti-androgen drugs or 
other biologic agents, and even novel single agents are currently being studied with 
mixed results [155].  However, as PCa advances the tumors metastasize to the bones and 
critical organs, while developing resistance to therapy, including taxane-based 
chemotherapy [155].  In order to develop more effective therapeutic alternatives for 
advanced PCa, there is a need to understand the mechanisms underlying tumor cell 
survival -pre and -post therapy [155].  
Our team and others have demonstrated that LEDGF/p75 overexpression in 
different cancers types and its potential role in chemoresistance, making this protein an 
attractive target for therapeutic targeting in cancer patients [31-33, 59, 89]. Importantly, 
LEDGF/p75 is not essential for cell viability under normal, non-stressful growth 
conditions since cancer cell lines with stable knockdown of this protein have been 
successfully developed [131, 156-157]. In vivo studies have shown that depletion of this 
protein is not embryonically lethal given that Psip1/LEDGF/p75-\- knockout mice were 
born alive despite suffering from multiple skeletal malformations that resulted in 
increased perinatal mortality due to inability to nurse [100].  However, under stress 
conditions that include chemotherapy, LEDGF/p75 plays an important role in cell 
survival.  This was highlighted by previous studies from our lab showing that 
overexpression of caspase cleavage fragments of LEDGF/p75 accelerated cell death in 
cancer cells only under stress conditions [26]. This makes this protein an attractive target 
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for the development of targeted therapeutic approaches in combination with cytotoxic 
drugs such as DTX that elevate intracellular levels of oxidative stress [33].  
The feasibility of targeting LEDGF/p75 in cancer cells has been demonstrated in 
various studies utilizing siRNAs and small hairpin RNA (shRNA) to transiently and 
stably knockdown its expression, respectively. Daugaard and colleagues utilized two 
different non-overlapping siRNAs (designated L1 and L3) to study the effects of 
LEDGF/p75 downregulation in various cancer cell lines [34]. They observed a decrease 
in cellular density and an increase in the number of round and detached cells when 
LEDGF/p75 expression was decreased in HeLa (cervical cancer), MCF-7 (breast cancer) 
and U2OS (osteosarcoma) cells. Cells depleted of LEDGF/p75 exhibited an increase in 
the volume of the acidic compartment, increased autophagosomes, and destabilization of 
their lysosomal membranes. They concluded from these findings that LEDGF/p75 
expression contributed to cell viability by stabilizing the lysosomal membranes [34]  
In a more recent study, Daugaard and colleagues used siRNA to decrease the 
expression of LEDGF/p75 in various human cancer cell lines and also in embryonic 
fibroblasts (MEFs) derived from Psip1/LEDGF-knockout mice [144]. They demonstrated 
that cells depleted of LEDGF/p75 were more susceptible to DNA-damaging agents such 
as ionizing radiation, camptothecin and mitomycin.  Knockdown of this protein impaired 
the ability of the cells to repair DNA double-strand breaks. LEDGF/p75 knockdown also 
inhibited the recruitment of CtIP, an important protein in the resection of DNA double-
strand breaks, to active chromatin sites , leading to DNA damage and cell death [144].   
In another study published by Bhargavan et al. [83], siRNA was also used to 
knockdown expression of LEDGF/p75 in DU145 prostate cancer cells and observe its 
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effects in various characteristics of tumor aggressiveness.  In their study, LEDGF/p75 
knockdown resulted in down-regulation of transactivation of the Hsp27 promoter, and 
decreased proliferation, migration, invasion and cell viability.  Knockdown of 
LEDGF/p75 also reduced proliferation in normal epithelial prostate cells (PWR-1E) 
although not as significant as in the DU145 cells. These authors also observed that cell 
cycle progression was interrupted at the S-phase and G2–M phase in cells depleted of 
LEDGF/p75, associated with downregulation of the ERK1/2-Akt pathway. The tumor 
aggressive properties of these cells were re-established when LEDGF/p75 was 
ectopically re-expressed [83].  
 Our group utilized siRNA to knockdown the expression of LEDGF/p75 in PC3 
and U2OS cells and demonstrated that LEDGF/p75 knockdown positively affects Hsp27 
promoter transactivation by its interacting partner, the transcriptional factor MeCP2, 
possibly through a feedback loop [82].  As mentioned above, our group also utilized 
siRNA to knockdown the expression of LEDGF/p75 in PC3 cells to identify target genes 
of this protein [79].  Leitz et al. [131] utilized both shRNA and siRNAs to silence the 
expression of LEDGF/p75 in HPV18-positive (HeLa) and HPV16-positive (SiHa, CaSki) 
cells. They observed that 3 non-overlapping shRNAs targeting LEDGF/p75 reduced the 
clonogenic capacity of these cells. LEDGF/p75 depletion also reduced clonogenicity in 
HPV-negative cells regardless of their p53 status. In addition, silencing of LEDGF/p75 
with siRNA sensitized cells to genotoxic agents such as hygromycin B, camptothecin 
(CPT), or 6 Gy γ-irradiation [131]. More recently, our group demonstrated that transient 
and stable downregulation of LEDGF/p75 in PC3 cells resulted in reduced transcript and 
protein expression of ERp57/GRP58, an oxidoreductase and chaperone of newly 
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synthetized glycoproteins [35].  Taken together, these studies demonstrate that 
LEDGF/p75 can be effectively targeted in cellular models to induce changes in cellular 
viability and tumorigenic properties. 
 
Repurposing HIV-Based LEDGF/p75 Inhibitors for Cancer Treatment 
LEDGF/p75 is widely recognized in the literature for its pivotal role in HIV-1 
integration and replication [158]. Numerous studies have validated the integrase binding 
domain (IBD) in the C-terminal region of LEDGF/p75 as a binding site for the catalytic 
domain of HIV-integrase (IN), facilitating HIV integration and replication (Figure 5) 
[158].  Current efforts are focusing on the development of novel antiviral drugs that 
disrupt the interaction between HIV-IN and the IBD of LEDGF/p75 [159].  Recent 
studies reported the use of peptidomimetics and small molecule inhibitors (SMIs) that 
disrupt this interaction, decreasing HIV-IN binding activity and viral replication [160-
161]. These studies point to LEDGF/p75 as a potentially druggable target, with 
implications for the treatment of HIV-AIDS and cancers overexpressing this protein.   
As mentioned above, previous studies from our group demonstrated that cleavage of 
LEDGF/p75 by caspases during apoptotic cell death resulted in fragments with a 
truncated IBD incapable of promoting cancer cell survival under stress conditions,   
possibly due to the inability of these fragments of tethering transcription factor cargo to 
chromatin [26, 35, 63].  Moreover, our group also showed that overexpression of 
LEDGF/p52, which lacks the IBD, promoted apoptosis in cancer cells [63].  These early 
studies provided initial evidence for the important role of the IBD in cancer cell survival. 
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Figure 5. The IBD region of LEDGF/p75 facilitates viral infection by interacting with 
HIV-IN and tethering the pre-integration complex to the host’s chromatin (Adapted from 
Suzuki et al. 2011).   
 
 
 
 
 36 
The feasibility of targeting LEDGF/p75, particularly its IBD region, in cancer has 
been recently demonstrated in the context of development novel treatments for MLL-
fusion driven leukemias [130]. These are genetically diverse and characterized by a poor 
prognosis [129]. As mentioned previously, MLL forms a ternary complex with menin 
(MEN1) and LEDGF/p75 that targets specific genes, inducing their activation or 
repression leading to increased leukemic transformation [129]. Structural and 
biochemical studies revealed that the LEDGF/p75 IBD interacts with menin and MLL 
and that this interaction occurs via the same binding site of other interacting partners of 
LEDGF/p75 including PogZ and JPO2 [128].  This domain then plays multiple roles in 
different contexts: transcriptional and pro-survival activities presumably through 
interactions with transcription factors and other chromatin-associated proteins, 
facilitating the tethering of MLL fusion proteins to chromatin in leukemia, and 
facilitating HIV-1 integration and infection.  Select SMIs designed to prevent HIV-1 IN 
and LEDGF/p75 complex formation through the IBD have shown antiviral properties 
without inhibiting IN enzymatic function [159, 162-163].  
Recognizing the therapeutic potential of the multi-functional IBD domain of 
LEDGF/p75, involved in protein-protein interactions and pro-survival functions, there is 
currently a strong interest in developing different agents targeting this region.  In one 
study, LEDGF/p75 interacting peptides known to inhibit the LEDGF/ p75–HIV-1 
integrase interaction were shown to impair clonogenic growth of primary murine MLL 
fusion–expressing leukemic cells and reduce ectopic HoxA9 expression [128].  Another 
group used peptides derived from LEDGF/p75 to disrupt the menin/MLL-LEDGF/p75 
complex and its subsequent pro-leukemogenic properties [85].  
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The development of targeted cancer therapy agents that destroy cancer cells by 
targeting oncogenic proteins or tumor-associated antigens (TAA) without affecting 
normal cells has significantly progressed during recent years [164].  Part of this effort 
includes the repurposing of agents that have been developed previously for the use in a 
different disease to be used adjunct to anti-cancer systemic therapeutic regimes, which 
could significantly improve clinical outcomes in chemoresistant cancers. For example, 
antiviral classes of compounds have been explored for their anti-cancer therapeutics 
against oncogenic kinases in a panel of cell lines including prostate, breast, and colon 
cancer [165].  Because of its dual role in HIV infection and cancer, LEDGF/p75 is an 
attractive target in anti-cancer therapy, with several classes of SMIs of the LEDGF/p75-
IN interaction reported in the literature with baseline cytotoxicity data in cancer cells. 
[160, 162-163, 166-168]. These inhibitors, originally designed to disrupt HIV integration, 
could potentially be repurposed for treatment of chemoresistant cancers in which 
LEDGF/p75 levels and activity are increased. An advantage of repurposing LEDGF/p75-
IN inhibitors in anti-cancer therapy is that they are likely to target the C-terminal IBD, 
thus disrupting LEDGF/p75-protein interactions that are important for cancer cell 
survival under stress, which may include chemotherapeutic stress [130].  
 
Summary Highlights 
• Treatment options for CRPC are limited and patients often develop resistance to 
therapy resulting in disease progression and decreased survival. 
• There is a critical need to identify and target novel oncoproteins that contribute to 
CRPC therapy resistance to reduce PCa mortality. 
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• LEDGF/p75 is an emerging stress oncoprotein that promotes cellular survival 
against a wide variety of environmental stressors, including oxidative stress, 
radiation, heat, serum starvation, and cytotoxic drugs. 
• LEDGF/p75 interacts with different transcription factors and chromatin binding 
proteins to transactivate specific stress survival- and cancer-associated genes 
depending on the microenvironment, cellular context, and stress stimuli.  
• LEDGF/p75 is overexpressed in several human cancers, including PCa, and 
promotes cancer cell aggressive properties such as cell proliferation, 
clonogenicity, migration, invasion, angiogenesis, tumor volume, and 
chemoresistance.  
• Targeting LEDGF/p75 with RNA interference or repurposed HIV-based 
LEDGF/p75 inhibitors is a promising strategy to re-sensitize chemoresistant 
CRPC to taxane therapy, leading to increased patient survival and decrease in the 
racial disparity mortalities associated with CRPC.   
 
Figure 6 illustrates our working model.  Briefly, environmental stress caused by 
various factors such as treatment with taxane drugs results in elevated intracellular ROS, 
leading to increased LEDGF/p75 expression. Overexpressed and activated LEDGF/p75 
then interacts with other co-transcription factors to upregulate the expression of stress 
survival proteins that contribute to aggressive cancer cell properties, including 
chemoresistance.  Tissue overexpression of LEDGF/p75 or extracellular release of this 
protein may also lead to autoantibody elicitation in susceptible individuals.     
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 Figure 6. LEDGF/p75 overexpression as a result of environmental stressors 
contributes to aggressive tumor properties. 
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Hypothesis and Purpose of Dissertation Work 
While the role of LEDGF/p75 in HIV integration and infection has been 
thoroughly studied over the past 15 years, this protein has recently attracted significant 
attention in the field of cancer research due to its pro-survival functions, including 
increasing resistance to chemotherapy, in cancer cells.  In a multidisciplinary effort, the 
knowledge obtained from studying viral integration and the availability of LEDGF/p75 
targeting agents (both siRNAs and repurposed SMIs) could be potentially be applied to 
the clinic to address the problem of PCa chemoresistance and the lack of effective 
treatment options at later stages of the disease.   
In this dissertation work, we explored the role of LEDGF/p75 in PCa 
chemoresistance, the mechanisms by which LEDGF/p75 might protect cells against 
taxane therapy, and the targeting of this protein in drug-resistant PCa cellular models 
using siRNAs and SMIs.  The overall hypothesis of this study is that elevated 
LEDGF/p75 expression promotes selective chemoresistance in PCa by antagonizing 
non-apoptotic/caspase-independent cell death, and that targeting this protein can 
contribute to effectively overcome the observed drug-resistance. The results obtained 
from this study will add to current efforts to develop effective therapeutic options to 
reduce chemotherapy resistance in CRPC patients.  
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Abstract 
Prostate cancer (PCa) is associated with chronic prostate inflammation resulting 
in activation of stress and pro-survival pathways that contribute to disease progression 
and chemoresistance. The stress oncoprotein lens epithelium-derived growth factor p75 
(LEDGF/p75), also known as DFS70 autoantigen, promotes cellular survival against 
environmental stressors, including oxidative stress, radiation, and cytotoxic drugs. 
Furthermore, LEDGF/p75 overexpression in PCa and other cancers has been associated 
with features of tumor aggressiveness, including resistance to cell death and 
chemotherapy. We report here that the endogenous levels of LEDGF/p75 are upregulated 
in metastatic castration resistant prostate cancer (mCRPC) cells selected for resistance to 
the taxane drug docetaxel (DTX). These cells also showed resistance to the taxanes 
cabazitaxel (CBZ) and paclitaxel (PTX), but not to the classical inducer of apoptosis 
TRAIL. Silencing LEDGF/p75 effectively sensitized taxane-resistant PC3 and DU145 
cells to DTX and CBZ, as evidenced by a significant decrease in their clonogenic 
potential. While TRAIL induced apoptotic blebbing, caspase-3 processing, and apoptotic 
LEDGF/p75 cleavage, which leads to its inactivation, in both taxane- resistant and -
sensitive PC3 and DU145 cells, treatment with DTX and CBZ failed to robustly induce 
these signature apoptotic events. These observations suggested that taxanes induce both 
caspase-dependent and -independent cell death in mCRPC cells, and that maintaining the 
structural integrity of LEDGF/p75 is critical for its role in promoting taxane-resistance. 
Our results further establish LEDGF/p75 as a stress oncoprotein that plays an important 
role in taxane-resistance in mCRPC cells, possibly by antagonizing drug-induced 
caspase-independent cell death. 
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Introduction 
Prostate cancer (PCa) represents a significant health burden in the United States 
since it is the most frequently diagnosed cancer in men and the second leading cause of 
male cancer deaths after lung cancer (1). The rates of PCa incidence and mortality are 
variable among different racial groups, with African American men presenting a 
isproportionately high incidence and mortality compared to other ethnic/racial groups [1, 
2]. Chronic inflammation of the prostate leading to an augmented state of cellular 
oxidative stress and activation of stress survival pathways has been linked to PCa 
pathogenesis and resistance to therapy [3–7]. 
Lens Epithelium-Derived Growth Factor of 75kD (LEDGF/p75) has recently 
emerged as a stress oncoprotein that promotes cellular survival against many different 
environmental stressors, including oxidative stress, radiation, heat, serum starvation, and 
cytotoxic drugs [8–20]. Also known as PC4 and SFRS1 interacting protein (PSIP1), and 
dense fine speckled autoantigen of 70 kD (DFS70), this protein has attracted considerable 
attention due to its broad relevance to cancer, autoimmunity, eye diseases, and HIV- 
AIDS [14, 15]. LEDGF/p75 is the target of autoantibody responses in a subset of patients 
with PCa [14, 21], as well as in patients with diverse chronic inflammatory conditions 
and some apparently healthy individuals [14]. While early studies suggested that 
LEDGF/p75 was a growth factor critical for the proliferation of lens epithelial cells [8], 
subsequent studies have demonstrated that this protein is not a lens specific growth factor 
but rather a ubiquitous nuclear transcription co-activator with oncogenic functions that is 
activated during the cellular response to stress [14, 15]. 
Our group and others have shown that LEDGF/p75 is upregulated in PCa and in 
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other human cancer types, and that overexpression of this protein in cancer cells is 
associated with features of tumor aggressiveness, such as increased proliferation, 
resistance to cell death and therapy, invasion, migration, clonogenicity, angiogenesis, and 
tumor growth [11, 15–25]. In a previous study we reported that LEDGF/p75 
overexpression in PCa cells promoted resistance against caspase-independent cell death 
induced through lysosomal membrane permeabilization (LMP) by the taxane drug 
docetaxel (DTX), the gold standard for advanced PCa chemotherapy [18]. These results 
were consistent with studies in other cancer cell types demonstrating that LEDGF/p75 
overexpression promoted cellular protection against LMP-inducing drugs [19]. More 
recently, we provided evidence that LEDGF/p75 overexpression in PCa cells promotes 
protection against necrotic cell death induced by oxidative stress [20]. 
The mechanisms by which LEDGF/p75 promotes resistance to stress-induced cell 
death have not been fully elucidated, although available evidence suggests that this 
oncoprotein is upregulated or activated in response to environmental stressors [8-14, 17-
20, 22, 24-25]. Acting as a transcription co-activator, it contributes to the transactivation 
of stress, antioxidant, and cancer-associated genes through interaction with transcription 
complexes involving RNA polymerase II, PC4 transcription factor, menin-MLL (mixed 
leukemia lineage), the MeCP2 transcription activator/repressor, and c-MYC-associated 
protein JPO2 [26–31]. LEDGF/p75 target genes include heat shock protein 27 (HSP27), 
oxidoreductase ERP57/ PDIA3/GRP58, cytoglobin (CYGB), peroxiredoxin 6 (PRDX6), 
involucrin, alcohol dehydrogenase, aldehyde dehydrogenase, αB-crystallin, gamma 
glutamylcysteine synthase, vascular endothelial growth factor C (VEGF-C), and 
interleukin 6 (IL-6) [12, 13, 20, 22, 23, 28, 32-41]. 
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Recent evidence points to LEDGF/p75 as a promising druggable target for HIV 
and leukemia therapy [42–44]. In light of our previous demonstration that LEDGF/p75 
overexpression in PCa cells promoted resistance to DTX [18], the present study was 
conducted to determine if targeting LEDGF/p75 in chemoresistant PCa cells would re-
sensitize these cells to the clinically relevant taxane drugs DTX and cabazitaxel (CBZ), 
which are the first and second line cytotoxic chemotherapeutic drugs, respectively, 
approved by the Food and Drug Administration (FDA) for the treatment of metastatic 
castration-resistant prostate cancer (mCRPC) [45, 46]. In addition, since LEDGF/p75 
promoted protection against DTX-induced lysosomal cell death and stress-induced 
caspase-independent cell death in PCa cells [18, 20], we explored if the protective 
functions of LEDGF/p75 are linked to the ability of DTX and CBZ to activate caspase-
independent mechanisms of cell death in drug-resistant PCa pre-clinical models. This 
study represents the first step in the development of a multi-targeting approach involving 
LEDGF/p75 in combination with taxanes to re- sensitize chemoresistant mCRPC cells to 
therapy. 
 
Results 
LEDGF/p75 is Overexpressed in DTX-Resistant DU145 and PC3 Cells 
We determined the expression of LEDGF/p75 in the DTX-resistant mCRPC cell 
lines DU145-DR and PC3-DR, compared to the drug sensitive parental DU145 and PC3 
cells. These cells were developed to be resistant to DTX by selecting and expanding the 
surviving cells after successive treatments with increasing concentrations of the drug. We 
observed that the expression of LEDGF/ p75 was significantly upregulated at the 
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transcript and protein level as DU145 and PC3 cells made the transition from 
chemosensitivity to chemoresistance (Figure 7). The DU145-DR cells displayed a 
significant 3.87 fold increase in LEDGF/p75 transcript expression compared to the 
parental DU145 cells (Figure 7A, left panel). To determine if the increase in transcript 
expression correlated with increased protein expression, we collected total lysates from 
DU145 and DU145-DR cells and performed immunoblotting using an antibody specific 
for LEDGF/p75. We observed that LEDGF/p75 was robustly expressed in the DU145-
DR cells compared to the parental cells (Figure 7B, left panel). To further confirm these 
findings, we then proceeded to analyze LEDGF/p75 expression by immunofluorescence 
microscopy using a well-characterized human autoantibody against this protein [47]. 
Acquiring the images under exactly the same parameters, we observed that the 
fluorescence intensity of nuclear dense fine speckles, corresponding to LEDGF/ p75 
staining [28, 47], in the DU145-DR cells was higher compared to the intensity in the 
chemosensitive DU145 cells (Figure 7C, left panel). 
The same experimental procedures were performed to assess LEDGF/p75 
expression in the PC3 and PC3-DR cells. When we compared the LEDGF/p75 transcript 
expression in these two cell lines, we observed a significant 3.60 fold increase in the 
transcript levels in PC3-DR compared to the sensitive PC3 cells (Figure 7A, right panel). 
As in DU145- DR cells, there was a robust increase in LEDGF/p75 protein expression in 
the PC3-DR cells compared to the parental PC3 cells (Figure 7B, right panel). Also, 
similar to DU145- DR cells, the fluorescence intensity of LEDGF/p75 staining in PC3-
DR cells was higher when compared under identical imaging conditions to the PC3 cells 
(Figure 7C, right panel). Taken together, these findings showed higher endogenous 
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expression of LEDGF/p75 in DTX-resistant cells at both the transcript and protein levels 
compared to their drug-sensitive parental cells. 
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Figure 7. LEDGF/p75 is overexpressed in DTX-resistant DU145 and PC3 cells. 
LEDGF/p75 transcript levels were quantified using mRNA isolated from DU145 and 
DU145-DR cells by qPCR in at least three independent experiments (A. left panel). 
Statistical significance was determined in comparison to control DU145 cells using 
Student’s t-test (** p<0.01). LEDGF/p75 protein expression was evaluated in lysates 
from DU145 and DU145-DR cells by immunoblotting using a rabbit anti-LEDGF/p75 
antibody that specifically detects this protein at 75kDa (B. left panel). β-actin was used as 
loading control. Fluorescence intensity of nuclear dense fine speckles characteristic of 
LEDGF/p75 was evaluated by indirect immunofluorescence microscopy in DU145 and 
DU145-DR cells, using a human anti-LEDGF/p75 autoantibody (C. left panel). 
LEDGF/p75 transcript levels were also quantified using mRNA isolated from PC3 and 
PC3- DR cells by qPCR in at least three independent experiments (A. right panel). P 
values were determined in comparison to control PC3 cells using Student’s t-test 
(**p<0.01). LEDGF/p75 protein expression was evaluated in lysates from PC3 and PC3-
DR cells by immunoblotting using a rabbit anti-LEDGF/p75 antibody (B. right panel). β-
actin was used as loading control. Fluorescence intensity of nuclear dense fine speckles 
characteristic of LEDGF/p75 was evaluated by indirect immunofluorescence microscopy 
in PC3 and PC3-DR cells, using a human anti-LEDGF/p75 autoantibody (C. right panel). 
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DU145-DR and PC3-DR Cells are Resistant to Multiple Taxanes but not to TRAIL 
We then investigated if the DTX-resistant PCa cells, which showed endogenous 
overexpression of LEDGF/ p75, were selectively resistant to DTX or also showed multi-
drug resistance, particularly to other taxanes such as CBZ and paclitaxel/taxol (PTX). 
Currently, CBZ is the second-line cytotoxic chemotherapeutic drug available for 
advanced PCa patients that develop resistance to DTX [45, 46]. We also included in our 
analysis PTX, the original taxane and parent drug of both DTX and CBZ. Although not 
currently used for clinical treatment of advanced PCa, PTX is commonly used in the 
treatment of other tumor types [48], and it was therefore important to determine if DTX-
resistant cancer cells overexpressing LEDGF/p75 also promote resistance to this parental 
taxane. We also treated our chemosensitive and chemoresistant PCa cells with tumor 
necrosis factor related apoptosis inducing ligand (TRAIL), an inducer of caspase-
dependent apoptosis. In previous studies we observed that while ectopic LEDGF/ p75 
overexpression promoted protection against stressors that induced caspase-independent 
cell death such as DTX and tert-butyl hydroperoxide (TBHP), it did not confer protection 
against classical inducers of caspase-dependent cell death such as TRAIL and 
staurosporine (STS) [18, 20]. Therefore, we sought to reproduce these observations in 
chemoresistant PCa cells naturally overexpressing LEDGF/ p75 after selection. 
For these studies, we treated DU145-DR cells and DU145 cells with increasing 
concentrations of DTX, PTX,or CBZ for upto 72hr, and TRAIL for upto 24 hr (Figure 
8A) and determined the approximate drugs’ half-maximal effective concentrations 
(EC50). We observed higher viability in DU145-DR cells treated with DTX (EC50 ≈ 200 
nM), and PTX (EC50 ≈ 300 nM), compared to DU145 cells, which showed EC50s of 10 
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nM and 20 nM, respectively. In the dose response curves, a statistically significant 
difference in the percentage of surviving cells could be observed at all concentrations 
(range 10-1000 nM). Interestingly, when we examined the difference in the overall 
survival between DU145- DR and DU145 cells treated with CBZ, there was a trend 
toward higher survival in the DU145-DR cells, with EC50 values of 11 nM in the 
DU145-DR cells and 2 nM in the DU145 cells. For CBZ, there was a statistically 
significant difference in survival at concentrations above 10 nM. We did not observe a 
difference in survival when DTX-resistant and -sensitive cell lines were treated with 
increasing concentrations of TRAIL. Both cell lines showed high sensitivity to low 
concentrations of this cell death ligand (10 ng/ml). 
Similar experiments with PC3-DR and PC3 cells revealed a statistically 
significant difference in the percentage of surviving PC3-DR cells compared to PC3 cells 
after exposure to DTX, with EC50s of 100 nM and 10 nM, respectively (Figure 8B). We 
also observed a statistically significant increased survival in PC3-DR cells exposed to 
PTX, with an EC50 of 1000 nM, compared to an EC50 of 100 nM for PC3 cells. 
Consistent with results obtained with the DU145-DR and DU145 cells, there was an 
overall trend in the difference in survival between PC3-DR cells and PC3 cells after 
treatment with CBZ. We obtained EC50s of 50 nM for PC3-DR and 5 nM for PC3 cells, 
with statistically significant differences at CBZ concentrations below 1 nM. Like in 
DU145 cells, we did not observe any differences when PC3-DR and PC3 cells were 
treated with TRAIL.  
We then proceeded to examine the morphology of the cells under the different 
treatment conditions (Figure 8C). We observed that DTX-resistant cells had a 
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relatively normal morphology with fewer floating cells and features of cell death, 
compared to the sensitive cell lines which clearly showed increased cell death when 
treated with DTX, PTX, or CBZ at the low pharmacological concentrations of 10 nM, 1 
µM, and 10 nM, respectively. Robust apoptotic cell death could be observed 
upon treatment with TRAIL. In summary, there was increased cell survival in the DTX-
resistant cell lines, which express high endogenous levels of LEDGF/p75, during 
treatment with increasing concentrations of the different taxanes. However, none of the 
cell lines showed resistance to TRAIL. 
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Figure 8. DU145-DR and PC3-DR cells are resistant to multiple taxanes but not to 
TRAIL. A. and B. Assessment of cell viability as measured by MTT assay in DU145 (red 
diamonds), DU145-DR (blue squares), PC3 (red triangles), and PC3-DR (crosses) cells 
treated with increasing concentrations of DTX (10nM, 50nM, 100nM, 500nM, and 
1000nM), PTX (10nM, 50nM, 100nM, 500nM and 1000nM), CBZ (0.1 nM, 1nM, 10nM, 
50nM and 100nM) for up to 72 hr, and TRAIL (10ng/ml, 20ng/ml, 50ng/ml, 80ng/ml and 
100ng/ml) for 24 hr. Each graph represents the average of at least three different 
experiments in triplicates normalized to untreated controls. Standard error of the mean 
(SEM) was calculated. Statistical significance was determined by comparing the values 
for each drug concentration in the DTX-sensitive DU145 and PC3 cells versus the DTX-
resistant DU145-DR and PC3-DR cells, respectively, using Student’s t-test (*p<0.05). C. 
Morphology of drug-sensitive and –resistant cells after treatment with DTX, PTX, CBZ, 
or TRAIL, visualized by Hofmann Modulation Contrast microscopy. Scale bar set at 20 
µM. 
 70 
LEDGF/p75 Depletion Sensitizes DTX-resistant PCa Cells to Clinically Relevant 
Taxanes 
Given that the transition from taxane sensitivity to resistance in PCa cells involves 
the upregulation of several survival pathways [49, 50], it was necessary to establish the 
contribution of LEDGF/p75 to the observed taxane resistance in DU145-DR and PC3-DR 
cells. For these experiments, we transiently knocked down LEDGF/p75 in our drug-
resistant models using small inhibitory RNAs (siRNAs) specific for this protein [20, 33]. 
We sought to determine if LEDGF/p75 knockdown alone decreased the clonogenic 
potential of taxane-resistant cells, and if its combination with drug treatment further 
sensitized the cells to taxane chemotherapy. We chose clonogenic assays for these 
experiments because they could clearly show cellular sensitization to the treatments over 
time by decrease in colony formation. The spatial constraints (96 well plates) that we 
encountered in short-term MTT viability assays did not permit to assess the long-term 
effects of drugs on cell growth. Colony formation assays have been widely used to 
determine the effects of LEDGF/ p75 knockdown on its tumorigenic properties as well as 
its ability to promote resistance to non-taxane drugs in non- PCa cell models [19, 23, 25, 
27, 51]. 
Transient knockdown of LEDGF/p75 in DU145-DR and PC3-DR cells led to 
robust depletion of the protein compared to cells transfected with scrambled duplex 
siRNA (siSD) control (Figure 9A and 9A). LEDGF/ p75 depletion was still robust 96 hr 
post-transfection in both cell lines, indicating that it was stable at the time the cells were 
treated with the DTX or CBZ during the initial hours of clonogenic growth (Figure 9A 
and 9A). We focused on DTX and CBZ on these and subsequent experiments because 
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they are the first and second line chemotherapeutic drugs, respectively, currently used for 
the clinical treatment of mCRPC. 
LEDGF/p75 depletion alone in DU145-DR cells in the absence of taxanes 
significantly reduced colony formation by 50.7% compared to untreated siSD control 
cells (Figure 9B, 9C, 9D). On the other hand, treatment with DTX alone, without 
LEDGF/p75 depletion, significantly reduced colony formation by 35% and 55.3% at 
concentrations of 50 nM and 100 nM, respectively, compared to the untreated siSD 
control cells (Figure 9C), indicating an EC50 for DTX alone of approximately 100 nM. 
However, the combination of LEDGF/p75 depletion plus 50 nM DTX or 100 nM DTX 
reduced colony formation by 75.2% and 83.4%, respectively, when compared to 
untreated SD-control cells (Figure 9C), and by 49.7% and 66.4%, respectively, when 
compared to LEDGF/p75 depletion alone (Figure 9D). These results indicated that the 
combination of DTX plus LEDGF/p75 depletion chemosensitized the cells, with EC50 < 
50 nM, compared to untreated cells. 
In the case of CBZ, this drug alone, without LEDGF/ p75 depletion, significantly 
reduced colony formation in DU145-DR cells by 14.2% and 41.8% at concentrations of 
0.1 nM and 1 nM, respectively, when compared to untreated siSD-control cells (Figure 
9B, 9C), indicating an EC50 above 1 nM. However, the combination of LEDGF/ p75 
depletion plus 0.1 nM CBZ or 1 nM CBZ reduced colony formation by 66.1% and 
83.8%, respectively, when compared to untreated siSD control cells (Figure 9C), and by 
31.2% and 67.1%, when compared to LEDGF/ p75 depletion alone (Figure 9D). These 
results indicated that the combination of CBZ plus LEDGF/p75 depletion 
chemosensitized the cells, with EC50 < 0.1 nM, compared to untreated cells. 
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DU145-DR cells transfected with siSD control oligos or si-LEDGF/p75 were equally 
sensitive to 100 ng/ml TRAIL, a concentration used in previous studies to efficiently 
induce caspase-dependent apoptosis [18, 21] and which did not yield any colonies 
(Figure 9B, 9C, 9D). These results were consistent with results shown in Figure 2 in 
which DU145 cells, both DTX sensitive resistant, were equally sensitive to a wide range 
of TRAIL concentrations (10 ng/ml-100 ng/ml). 
We then performed similar studies to determine the effects of transient 
LEDGF/p75 depletion in PC3-DR cells, with and without drug treatment. We observed a 
significant decrease (24.4%) in the clonogenicity of PC3- DR cells after LEDGF/p75 
depletion compared to the siSD control cells, although the effect was not as robust as in 
the DU145-DR cells (Figure 10B, 10C). Treatment with DTX alone, without LEDGF/p75 
depletion, reduced PC3-DR colony formation by 10.4% and 18.6% at concentrations of 
50 nM and 100 nM, respectively, compared to the untreated siSD control cells (Figure 
10C), indicating an EC50 well above 100 nM. However, the combination of LEDGF/p75 
depletion plus 50 nM DTX or 100 nM DTX reduced colony formation in the PC3-DR 
cells by 46.7% and 57.9%, respectively, when compared to untreated SD-control cells 
(Figure 10C), and by 29.5% and 44.4%, respectively, when compared to LEDGF/ p75 
depletion alone (Figure 10D). These results indicated that the combination of DTX plus 
LEDGF/p75 depletion chemosensitized the cells, with an EC50 between 50 and 100 nM, 
compared to untreated cells. 
Treatment of PC3-DR cells with CBZ alone, without LEDGF/p75 depletion, 
significantly reduced clonogenicity by 7.7% and 24.1% at concentrations of 0.1 nM and 1 
nM, respectively, when compared to untreated siSD-control cells (Figure 10C), indicating 
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an EC50 well above 1 nM. However, the combination of LEDGF/p75 depletion plus 0.1 
nM CBZ or 1 nM CBZ reduced PC3-DR colony formation by 36.2% and 54.2%, 
respectively, when compared to untreated siSD control cells (Figure 10B), and by 15.6% 
and 39.4%, when compared to LEDGF/p75 depletion alone (Figure 10D). These results 
indicated that the combination of CBZ plus LEDGF/p75 depletion chemosensitized the 
cells, with EC50 < 1 nM, compared to untreated cells. 
Like in DU145-DR cells, we also observed that PC3-DR cells transfected with 
siSD control oligos or si- LEDGF/p75 were equally sensitive to 100 ng/ml TRAIL. Taken 
together, these results showed that LEDGF/p75 depletion in DU145-DR and PC3-DR 
cells significantly diminished their clonogenicity, an effect that was enhanced in 
combination with taxanes. 
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Figure 9. Transient knockdown of LEDGF/p75 sensitizes DU145-DR cells to clinically 
relevant taxanes DTX and CBZ. A. LEDGF/p75 knockdown was confirmed by 
immunoblotting using a rabbit anti-LEDGF/p75 antibody in DU145-DR cells transfected 
with si-LEDGF/p75 oligos as compared to cells transfected with the siSD control oligos. 
B. Representative images of colony formation assay plates showing a decrease in 
clonogenicity in DU145-DR cells with LEDGF/p75 depletion compared to siSD control 
cells, in the presence and absence of drugs. Colonies were counted after 12 days of 
treatment. C. Bar graph showing quantification of DU145-DR colonies. Each bar 
represents the average of colonies counted in at least three independent experiments. 
SEM was calculated. D. Bar graph showing the percent clonogenicity in DU145-DR cells 
with LEDGF/p75 depletion, in the presence and absence of drug treatment, compared to 
untreated cells. Data was derived from the bar graph shown in panel C. SEM was 
calculated. Statistical significance was determined by comparing the values for cells 
transfected with siSD control oligos vs cells with LEDGF/p75 knockdown 
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Figure 10. Transient knockdown of LEDGF/p75 sensitizes PC3-DR cells to clinically 
relevant taxanes DTX and CBZ. A. LEDGF/p75 knockdown was confirmed by 
immunoblotting using a rabbit anti-LEDGF/p75 antibody in PC3-DR cells transfected 
with si-LEDGF/p75 oligos as compared to cells transfected with the siSD control oligos. 
B. Representative images of colony formation assay plates showing a decrease in 
clonogenicity in PC3-DR cells with LEDGF/p75 depletion compared to siSD control 
cells, in the presence and absence of drugs. Colonies were counted after 12 days of 
treatment. C. Bar graph showing quantification of PC3-DR colonies. Each bar represents 
the average of colonies counted in at least three independent experiments. SEM was 
calculated. D. Bar graph showing the percent clonogenicity in PC3-DR cells with 
LEDGF/p75 depletion, in the presence and absence of drugs, compared to untreated cells. 
Data was derived from the bar graph shown in panel C. SEM was calculated. Statistical 
significance was determined by comparing the values for cells transfected with siSD 
control oligos vs cells with LEDGF/p75 knockdown, in the presence or absence of drugs, 
using Student’s t-test (*p<0.05). 
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LEDGF/p75 Retains Structural Integrity During Taxane-Induced Cell Death but is 
Robustly Cleaved During TRAIL-Induced Apoptosis 
We showed previously that PCa cells with ectopic overexpression of LEDGF/p75 
were more resistant to DTX- induced lysosomal cell death and to oxidative stress-induced 
necrosis, but not to classical apoptosis inducers such as TRAIL and stauroporine (STS) 
[18, 20]. In addition, studies from our group showed that during caspase-dependent cell 
death triggered by classical apoptosis inducers (e.g., Fas, TRAIL, STS, etoposide), 
LEDGF/p75 is cleaved by caspases-3 and -7, generating various cleavage fragments, 
including a signature fragment of 65 kD that lacks pro- survival activity and exacerbates 
cell death in the presence of stress [11, 20–21]. We also demonstrated that this protein 
has a short splice variant, LEDGF/p52, which induces apoptosis when ectopically 
overexpressed leading to LEDGF/p75 cleavage and impaired ability to transactivate 
stress survival genes [52]. Together, these observations suggested that the stress 
protective effects of LEDGF/p75 are more relevant in the context of cellular resistance to 
stress-induced caspase-independent cell death, where lack of caspase activation results in 
preservation of LEDGF/p75 structural integrity, which is essential for its transcriptional 
and stress survival functions [11, 32, 52]. 
In light of these previous observations and the observed contribution of 
LEDGF/p75 to cellular resistance to taxanes but not TRAIL, we designed experiments to 
determine if the structural integrity of LEDGF/p75 is preserved during taxane-induced 
cell death. For these studies, we treated DTX-sensitive and -resistant DU145 and PC3 
cells with concentrations of DTX (100 nM), CBZ (100 nM), or TRAIL (100 ng/ ml) that 
caused cell death in the previous experiments (Figures 8-10). We first examined by 
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Western blotting if there was caspase-3 processing under these treatments, which would 
be indicative of activation of caspase- dependent apoptosis, using an antibody that 
specifically recognizes cleaved caspase-3 (Figure 11A). We observed the appearance of 
strong bands corresponding to cleaved caspase-3 fragment in lysates from both DTX- 
sensitive and -resistant cells treated with TRAIL. However, we did not detect robust 
processing of caspase-3 in DU145 or PC3 cells, both sensitive and resistant, 72 hr after 
exposure to 100 nM DTX, in spite of observing significant cell death at this concentration 
and time point, particularly in the sensitive cells, in previous experiments (Figure 8). 
Overexposure of chemiluminescent blots to film did not result in increased detection of 
caspase-3 cleavage in cells treated with DTX or CBZ (data not shown). There was a 
slight detection of cleaved caspase-3 in DU145 cells treated with 100 nM CBZ (Figure 
11A), in spite of the extensive loss of cell survival observed at this concentration in 
previous experiments (Figure 8). These experiments suggested that while TRAIL clearly 
induces caspase-dependent cell death in these cell lines, both sensitive and resistant, DTX 
and CBZ did not induce a comparatively robust caspase-3 processing and activation at 
the relatively high pharmacological concentrations used. 
We then proceeded to determine if LEDGF/p75 was cleaved during the same 
experimental conditions. As expected, we observed robust cleavage of LEDGF/ p75 into 
its signature apoptotic 65 kD fragment in DU145 and PC3 cells, both sensitive and 
resistant, treated with TRAIL (Figure 11B). This fragment was detected using human 
anti-LEDGF/p75 autoantibodies, which recognize a C-terminal autoepitope region that is 
preserved in the apoptotic cleavage fragments [11, 20]. However, LEDGF/p75 was 
minimally cleaved during the 72 hr treatment with 100 nM DTX in all cell lines (Figure 
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11B). 
Although cleavage was more visible, albeit still weak, in cells treated with 100 
nM CBZ, it did not achieve the robustness of the cleavage induced by TRAIL (Figure 
11B). These results were consistent with the observed minimal processing of caspase-3 
during taxane-induced cell death, with robust processing during TRAIL-induced 
apoptosis (Figure 11A). 
In light of these results we proceeded to examine closely the morphology of 
DU145 and PC3 cells, both DTX-sensitive and -resistant, treated with 100 nM DTX, 100 
nM CBZ, or 100 ng/ml TRAIL to assess the features of cell death (Figure 11C). The 
TRAIL-treated cells exhibited the classical apoptotic morphology characterized by 
extensive blebbing and shrinkage. By contrast, cells exposed to DTX and CBZ exhibited 
rounding and floating, consistent with mitotic arrest and catastrophe, as well as cells that 
appeared to be swollen and with breakage of the cell membrane. While there were cells 
displaying apoptotic blebbing, this feature was not as prominent in the taxane-treated 
cells as in the cells treated with TRAIL. These results are consistent with the observation 
of robust caspase-3 processing and LEDGF/p75 cleavage during TRAIL-induced cell 
death (Figure 11A) but not during taxane treatment (Figure 11B). 
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Figure 11. Caspase-3 processing and LEDGF/p75 cleavage in mCRPC cells treated with 
taxanes and TRAIL. A. Caspase-3 processing was detected by immunoblotting using an 
antibody specific for its large subunit (17/19 kD). Whole lysates were obtained from 
DU145, DU145-DR, PC3 and PC3-DR cells after treatment with DTX or CBZ (100nM) 
for 24, 48 and 72 hr, or TRAIL (100ng/ml) for 6, 12, and 24 hr. Untreated cells were used 
as controls. β-actin was used as loading control. B. LEDGF/p75 cleavage was assessed 
using a human anti-LEDGF/p75 autoantibody that specifically detects this protein (75 
kD) and its main apoptotic cleavage fragment (65 kD). Whole lysates were obtained from 
cells after treatment with DTX or CBZ (100nM) for 24, 48 and 72 hr, or TRAIL 
(100ng/ml) for 6, 12, and 24 hr. Untreated cells were used as controls. β-actin was used 
as loading control. C. Cell morphology was assessed by Hofmann Modulation Contrast 
microscopy to visualize features of cell death after drug treatment. Scale bar set at 20 µM. 
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LEDGF/p75 Depletion Does Not Influence the Expression of the Multidrug Resistance 
Protein P-glycoprotein in DTX-Resistant PCa Cells 
The molecular mechanisms by which LEDGF/ p75 promotes taxane resistance are 
relatively unknown, although they are likely linked to its ability to transcriptionally co-
activate stress survival genes. Given the established role of multidrug resistance or 
transporter proteins such as P-glycoprotein (P-gp, also known as ABCB1 or MDR1) in 
PCa chemoresistance [53, 54], we speculated that LEDGF/p75 might upregulate this 
protein in taxane resistant cells. For these experiments, we first compared the expression 
of P-gp in DU145-DR and PC3- DR cells to the drug-sensitive, parental DU145 and PC3 
cells. Consistent with its role in chemoresistance, P-gp was not expressed in the sensitive 
cell lines but was highly expressed in the drug-resistant cells (Figure 12A). We then 
determined if transient LEDGF/p75 depletion (up to 72h) in the taxane resistant cells led 
to downregulation of P-gp (Figure 12B). Our results indicated that LEDGF/p75 depletion 
had no effect on P-gp expression levels in DU145-DR and PC3- DR, suggesting that P-gp 
is not a target gene of this stress transcription co-activator. 
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Figure 12. LEDGF/p75 depletion in DTX-resistant cells does not lead to downregulation 
of P-glycoprotein. A. Immunoblots showing increased P-glycoprotein (P-gp) expression 
in DU145-DR and PC3-DR cells compared to the DTX sensitive, parental cell lines. B. 
Immunoblots showing that transient depletion (72 hr) of LEDGF/p75 in DU145-DR and 
PC3-DR does not attenuate P-gp expression. β-actin was used as loading control. 
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Discussion 
Our understanding of mechanisms underlying mCRPC has improved the 
outcomes for the management of this disease, with new therapeutic regimens that include 
sipuleucel-T, denosumab, abiraterone acetate, enzalutamide, and taxane therapy [55]. 
Unfortunately, despite these advances and overall increase in patient survival, mCRPC is 
still a challenging disease to manage, with most patients dying within three years of 
diagnosis due to therapy resistance, particularly to taxanes [49, 50, 53, 55-58]. The goal 
of the present study was to further establish the role of LEDGF/p75 in PCa taxane 
resistance and its potential as a novel therapeutic target for overcoming this resistance. 
Our group and others have provided evidence for the role of this protein in promoting 
tumor aggressive properties and chemoresistance in various cancer types [11, 17-20, 22-
27]. We reported previously that stable overexpression of LEDGF/p75 in PC3 cells 
attenuated DTX-induced caspase-independent cell death caused by LMP, as well as 
oxidative stress-induced necrosis, but not to the apoptosis inducers TRAIL and STS [18, 
20]. Given its role as a stress transcription coactivator, LEDGF/p75 activation by cancer 
cells is likely to counter rapid increases in oxidative stress that might overwhelm cellular 
antioxidant defense mechanisms and induce DNA damage and LMP. 
In this study we used mCRPC cellular models (PC3 and DU145) that were 
selected over time for their acquired resistance to DTX. While multiple mechanisms of 
taxane- resistance likely operate in these cells, we focused on LEDGF/p75 given our 
previous observations linking its ectopic overexpression to DTX resistance in mCRPC 
cells [18]. Our results clearly demonstrated the upregulation of endogenous LEDGF/p75 
in DU145-DR and PC3-DR cells. This upregulation did not appear to occur during short-
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term exposure to DTX because cells treated with increasing concentrations of DTX for 
up to 48 hr did not show LEDGF/ p75 upregulation (data not shown). However, as we 
selected chemoresistant clones after weeks of exposure to increasing concentrations of 
DTX, we began to detect elevated endogenous LEDGF/p75 levels, suggesting that this 
stress protein contributes to the selection of surviving cells in the presence of DTX. 
Our results also showed that DTX-resistant DU145 and PC3 cells displayed 
increased resistance to PTX and CBZ, compared to sensitive cells, at a wide range of 
pharmacological concentrations. However, both DTX-sensitive and -resistant cell lines 
showed robust sensitivity to TRAIL. These results suggested that the mechanisms of 
DTX resistance operating in these cells could also apply to PTX and CTX resistance, but 
not to TRAIL. The exquisite sensitivity of taxane-resistant cells to TRAIL suggests that 
apoptosis induction via death receptor signaling could be used to bypass the cellular 
protective functions of LEDGF/p75 and other survival proteins that are susceptible to 
caspase- mediated cleavage and inactivation. Unfortunately, efforts to target TRAIL 
receptors in clinical trials have been tempered by increased toxicity to cancer patients, 
most likely due to the high levels of these receptors in normal tissues [59]. 
Recent efforts to target LEDGF/p75 in the context of HIV-AIDS and leukemia 
have provided “proof-of- principle” that this protein is a druggable molecular target [27, 
43, 44, 51, 60]. We reasoned that if LEDGF/ p75 upregulation occurs during 
development of taxane chemoresistance, then targeting this protein in pre- clinical 
mCRPC models in combination with taxanes would sensitize sub-populations of resistant 
tumor cells to these drugs. Our results revealed that transient LEDGF/p75 depletion by 
itself, without drug treatment, attenuated the clonogenicity of both DTX-sensitive and -
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resistant PC3 and DU145 cells, consistent with results from other groups using other 
tumor cell models [19, 25]. It should be noted, however, that LEDGF/p75 is not essential 
for cell viability under normal growth conditions since cancer cell lines with stable 
knockdown of this protein have been effectively developed [20, 28]. Also, 
PSIP1/LEDGF/p75-\- knockout mice were viable despite suffering from multiple skeletal 
malformations leading to increased perinatal mortality [61]. However, under stress 
conditions, LEDGF/p75 plays a key role in enhancing cell survival [13, 14]. 
Our results also showed that LEDGF/p75 depletion in combination with DTX or 
CBZ significantly decreased the clonogenic potential of both DU145-DR and PC3-DR 
cells, particularly at higher, albeit still pharmacological, drug concentrations. Given the 
limited range of taxane concentrations used in our clonogenic assays, it was not possible 
to determine with precision the exact EC50 values for drug-resistant DU145 and PC3 
cells treated with either DTX or CBZ, with or without LEDGF/p75 depletion. While our 
results suggest a possible additive effect of the combinatorial treatment of taxanes plus 
LEDGF/p75 depletion, we cannot rule out the possibility that this combination acts 
synergistically to re-sensitize resistant cells. This could be explored in future studies by 
applying the Chou Talalay statistical method [62] to results from experiments in which a 
broad range of concentrations of both taxanes and small molecule inhibitors of 
LEDGF/p75 are combined. Our data also indicated that the anti-survival effects of 
LEDGF/p75 silencing was more pronounced in DU145- DR cells, consistent with the 
previous observation that LEDGF/p75 silencing in DU145 cells impairs their aggressive 
properties [23]. 
LEDGF/p75 silencing did not completely sensitize resistant cells to DTX and 
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CBZ, most likely due to the contribution of other independent mechanisms, possibly 
involving clusterin and P-gp drug transporter, to taxane resistance [49, 50, 53, 54]. 
Indeed, our results demonstrated that LEDGF/p75 depletion does not downregulate P-gp 
in taxane-resistant cells, suggesting that these two proteins act independently of each 
other. We cannot rule out, however, that LEDGF/p75 may transcriptionally activate P-gp 
in resistant cells but the cellular stability of this drug transporter may not make it 
susceptible to downregulation in response to LEDGF/ p75 depletion. Interestingly, a 
previous study showed that while P-gp is dramatically upregulated in several 
chemoresistant PCa cell lines, its inhibition reversed the resistant phenotype on a cell-line 
dependent manner, which would be consistent with the notion that multiple mechanisms 
of drug resistance may be activated in prostate tumor cells in response to chemotherapy 
[54]. Identifying resistance mechanisms independent of P-gp is therefore important since 
targeting this drug- transporter has not been highly successful because of the complexity 
of toxicity, adverse side effects, and altered pharmacokinetics encountered in studies 
[63]. 
Maintaining the structural integrity of LEDGF/ p75, particularly its C-terminal 
domain, is essential for its transcriptional and stress survival functions [11, 32, 52]. 
During apoptosis, caspase-3 mediated cleavage removes the extreme N-terminal and C-
terminal regions of LEDGF/p75, abrogating its stress survival functions [11]. This could 
explain why LEDGF/ p75 overexpression in cancer cells typically does not confer 
protection against insults that robustly activate caspase-3, such as TRAIL and STS, which 
result in LEDGF/p75 cleavage and inactivation, but does protect against insults that 
induce LMP and even necrotic cell death, which leave the protein relatively intact [18, 
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19, 64]. While several reports have underscored the anti- apoptotic role of LEDGF/p75 in 
cancer cells, the exact mode of cell death, and the possibility that caspase- dependent and 
caspase-independent pathways operate in parallel under the experimental conditions used, 
have not been fully characterized in these studies [17, 23, 24, 65]. Nevertheless, it is 
plausible that LEDGF/p75 could promote protection against apoptosis if this mode of cell 
death occurs downstream of events antagonized by this protein such as DNA damage and 
LMP [18-19, 24, 64].  
Our observation that DTX and CBZ did not induce robust caspase-3 processing 
and LEDGF/p75 cleavage at relatively high pharmacological plasma concentrations that 
induce cell death (100 nM), suggests that insufficient apoptosis induced by taxanes may 
lead to drug resistance by preserving the structural integrity of LEDGF/p75 and other 
stress survival proteins that otherwise would be cleaved and inactivated during apoptotic 
caspase-3 activation (Figure 7). In a previous study, we showed that caspase-3 activity 
and LEDGF/p75 cleavage could be induced in PC3 cells, albeit not robustly, at 
micromolar concentrations of DTX [18]. While high micromolar DTX concentrations are 
detected in plasma of cancer patients early after drug administration, typically they drop 
to the low nanomolar range a few days post- treatment, which may prevent induction of 
robust and sustained tumor cell apoptosis [66]. Consistent with this, a recent study 
indicated that intratumoral accumulation of DTX and CBZ is key for their efficacy, with 
development of DTX resistance occurring if accumulation of this drug is insufficient 
[67]. 
The limited caspase-3 processing and LEDGF/ p75 cleavage in taxane treated 
mCRPC cells observed in this study is consistent with the recent observation that DTX is 
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a poor inducer of caspase-dependent apoptosis in DU145 cells [68], and our previous 
observation that DTX induces both caspase-dependent and caspase- independent 
lysosomal cell death in PC3 cells [18]. It is likely that induction of both caspase-
dependent and -independent cell death by taxanes occurs in parallel in the tumor 
microenvironment, and that depending on the cellular context and local drug 
concentration, one cell death mode may be preferred over the other [18, 69, 70]. This 
then raises the intriguing question of whether there are intrinsic mechanisms in mCRPC 
tumors, such as upregulation of LEDGF/p75 and other stress oncoproteins, that favor 
promoting resistance to taxane- induced caspase-independent cell death. Although the 
mechanisms of cellular resistance to taxanes are not completely understood, current 
evidence points to tubulin mutations, multidrug transporters, androgen receptor-
mutations, and overexpression of transcription factors and stress proteins such as Stat1, 
Stat3, NF-kB, Hsp27, and Clusterin [49, 50, 53, 54, 71]. It remains to be established, 
however, whether some of these mechanisms effectively antagonize taxane-induced 
caspase-independent cell death. If this turns out to be the case, then targeting multiple 
molecular pathways that protect tumor cells against both caspase-dependent and caspase-
independent cell death could be an effective strategy to overcome taxane resistance in 
mCRPC. Since LEDGF/p75 appears to be a novel promoter of mCRPC cell resistance to 
taxane-induced caspase-independent cell death, this protein could be considered as a 
promising therapeutic target to overcome this resistance in combinatorial therapies. 
Finally, understanding the complex mechanisms underlying LEDGF/p75-
promoted taxane resistance will require a close examination of the regulatory 
mechanisms controlling the expression of this stress protein during PCa transition to 
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chemoresistance. To date, known mechanisms of LEDGF/p75 regulation include its 
activation by transcription factor Sp1 [72, 73], as well as repression by sumoylation, 
TGF-β, Bcl-2, ERK, and its small splice variant LEDGF/p52 [52, 74–76]. A crosstalk 
between LEDGF/p75 activation and the STAT3/IL6 inflammatory pathway, implicated in 
PCa, has also been identified in HaCaT skin cancer cells and in breast cancer cells [41, 
77]. Future studies will explore whether acquisition of taxane- resistance in mCRPC 
involves activation or suppression of LEDGF/p75 regulatory mechanisms. 
 
 90 
 
 
 
 
 
Figure 13. Model illustrating the potential role of LEDGF/p75 in the attenuation of drug-
induced caspase-dependent and –independent cell death. 
 91 
Materials and Methods 
Cell Lines, Antibodies and Reagents 
The metastatic PCa cell lines DU145 (brain metastasis) and PC3 (bone 
metastasis) were purchased from the American Type Culture Collection (ATCC) (Cat.# 
HTB-81 and Cat.# CRL-1435, respectively). Cells were cultured following supplier’s 
instructions in RPMI medium (Life Technologies – Thermo Fisher Scientific) 
supplemented with 10% fetal bovine serum (FBS), penicillin/streptomycin, and 
gentamicin. Cells were maintained in a humidified incubator with 5% CO2 at 37°C. The 
DTX-resistant cell line variants were developed as described previously [20]. Briefly, 
DU145 and PC3 cells were cultured in media containing 1 nM DTX and then surviving 
cells were passaged four times before increasing the concentration of DTX. This was 
repeated until resistant cells could be maintained with minimal cell death in media 
containing 10 nM DTX. 
The following commercially acquired antibodies were used: rabbit polyclonal 
anti-LEDGF/p75 (1:1000, Bethyl Laboratories Inc. catalog# A300-848A); rabbit 
monoclonal anti-β-actin (1:5000, Cell Signaling catalog # 5125); rabbit polyclonal anti-
cleaved caspase-3 (1:1000, Cell Signaling catalog # 9661); rabbit monoclonal anti- P-
gp/MDR1/ABCB1 (1:1000, Cell Signaling catalog # 13342) and horseradish peroxidase 
(HRP)-labeled secondary IgG antibodies (goat anti-rabbit IgG, 1:5000, Thermo Fisher 
Scientific catalog # 31466; goat anti- human IgG/IgA/IgM, 1:5000, Thermo Fisher 
Scientific catalog # A18847). The human autoantibody to LEDGF/ p75 (1:200) was from 
the serum bank of the Casiano Laboratory at the Center for Health Disparities and 
Molecular Medicine at Loma Linda University School of Medicine. The following 
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cytotoxic drugs were used: DTX (LC-Laboratories), PTX (Sigma-Aldrich), and CBZ 
(Sanofi-Aventis). TNF-related apoptosis inducing ligand (TRAIL) was purchased from 
Peprotech and Actinomycin D was purchased from R&D Systems. 
 
Viability Assays 
PCa cells were treated with the different taxane drugs at the selected 
concentrations for up to 72 hr, or with TRAIL plus 100 ng/ml Actinomycin D for up to 
24 hr. Cell morphology was visualized on an Olympus IX70 microscope equipped with 
Hoffmann Modulation Contrast (Olympus American) and a digital Spot Imaging System 
(Diagnostic Instruments). To assess viability, cells were seeded in 96-well plates at a 
density of 1x104 cells per well and then treated with each individual drug in at least 
triplicates. A modified 3-(4,5-dimethylthiazol- 2-yl)-2,5- diphenyltetrazolium bromide 
(MTT) assay (Sigma-Aldrich) was performed as described previously [18]. Absorbance 
was measured at 450 nm using a µQuant microplate reader (Bio-tek Instruments). Values 
were normalized to the absorbance obtained for the untreated, control cells. The 
approximate drug half- maximal effective concentration (EC50) was determined using 
the plotted values of the dose response curve. Each value represents the mean value of at 
least three different experiments in triplicates. The standard error of the mean (SEM) was 
calculated for each value. 
 
Quantitative Real-Time PCR 
Quantitative Real-Time PCR (qPCR) was performed as described previously [28]. 
Briefly, Total RNA was extracted from cells using the RNeasy plus mini kit (Qiagen). 
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The iScript cDNA synthesis kit (BioRad) was used to reverse transcribe RNA (0.5 µg) 
into cDNA. qPCR was performed using the MyiQ real-time PCR detection system with 
primers using iQ SYBR Green Supermix (BioRad) following manufacturers’ 
recommendations. Primer sequences for LEDGF/p75 were designed using the Primer3 
software. Forward sequence (5’ to 3’) was TGCTTTTCCAGACATGGTTGT and reverse 
sequence (3’ to 5’) was CCCACAAACAGTGAAAAGACAG. Primers were 
commercially synthetized by Integrated DNA Technologies (IDT). Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) mRNA was used for normalization. Data was 
normalized to values of corresponding controls and analyzed in three different 
experiments, each in triplicates. 
 
Immunoblotting Procedures 
Immunoblotting was performed as described previously [28]. Briefly, equal 
amounts of protein from whole cell lysates were separated using sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS- PAGE, NuPAGE 4–12%, Thermo Fisher 
Scientific) and transferred into polyvinyl difluoride (PVDF) membranes (Millipore). 
Membranes were blocked in 5% dry milk or 5% Bovine Serum Albumin (BSA), 
depending on the primary antibody, prepared in TBS-T buffer (20 mM Tris- HCl, pH 7.6, 
140 mM NaCl, 0.1% Tween 20). Membranes were then probed individually with primary 
antibodies and corresponding secondary antibodies and washed several times with TBS-T 
between each antibody application. Enhanced chemiluminescence (ECL) was used to 
detect immunoreactive protein bands. For this, the ECL Western Blotting Substrate 
(Thermo Fisher Scientific Pierce, catalog # 32106) was added to the antibody-protein 
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surface of each membrane, followed by incubation for 5 minutes. Membranes were then 
transferred to autoradiography cassettes and exposed to autoradiography films for 
different lengths of time to ensure accurate detection of immunoreactive protein bands. 
 
Indirect Immunofluorescence Microscopy 
To visualize endogenous LEDGF/p75 expression, cells were grown on coverslips, 
washed with PBS, then fixed with 4% formaldehyde and permeabilized with 0.5% Triton 
X-100. Cells were then incubated with human anti-LEDGF/p75 serum autoantibody [47] 
at 1:200 dilution for one hour in a humid chamber. After washes with PBS, cells were 
incubated with a FITC-conjugated goat anti-human IgG (H+L) secondary antibody 
(1:200, Thermo Fisher Scientific catalog # 62-7111), used at 1:200 dilution. Cells were 
mounted and counterstained with medium containing 4’,6-diamidino-2- phenylindole 
(DAPI) (Vectashield). Images were acquired in a BioRevo Keyence BZ-9000 fluorescent 
microscope (Keyence). All images corresponding to a particular fluorescent dye were 
obtained using the same parameters. 
 
RNA Interference-Mediated Knockdown of LEDGF/p75 in PCa Cells 
To achieve transient knockdown of LEDGF/p75 in our cellular models, specific 
short inhibitory RNAs (siRNAs) were used as described previously [20, 33]. Specifically, 
the si-LEDGF/p75 sequence corresponded to nucleotide sequence 1340–1360 (‘5-
AGACAGC AUGAGGAAGCGAdTdT-3’), present in a region in the C-terminus of 
LEDGF/p75 that is not shared by its short alternative splice variant LEDGF/p52. Cells 
were transfected with 100 nM siRNAs using Oligofectamine (Life Technologies) 
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following manufacturer’s instruction. A scrambled siRNA duplex (siSD, Darmacon) was 
used as a negative control. 
 
Clonogenic Assays 
Cells with and without LEDGF/p75 knockdown were cultured at a density of 
1x103 per well in 6-well plates and treated with increasing concentrations of DTX or 
CBZ, or a single concentration of TRAIL combined with Actinomycin D. Cells were 
grown for 12 days, which is when the surviving colonies were visible. After removing the 
media, the colonies were washed with PBS and fixed using a 3:1 methanol:acetic acid 
solution. PBS was used to wash the remaining fixing solution and then a solution 
containing 0.5% crystal violet diluted in methanol was then added to stain the colonies. 
Finally, the crystal violet was removed by washing with water and plates were air dried 
overnight. Images of each individual plate were acquired using the VisionWorks 
Acquisition and Analysis software in a GelDoc-It2 imager (UVP, Analytik Jena 
Company). The parameters to obtain the images were the same for all the plates. The 
Automated Colony Counting capability of the software was used to count each colony in 
the individual wells using the same parameters for each plate. At least three plates from 
three independent experiments were used for quantification of colonies under a particular 
experimental condition or treatment. 
 
Statistical Analysis 
The Student’s t-test (paired, two-tailed) was used to evaluate differences between 
treatment and control groups using Microsoft Excel. Differences were considered 
statistically significant at P values equal or below 0.05. 
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CHAPTER THREE 
SELECTED UNPUBLISHED DATA 
Possible Role of LEDGF/p75 in Protecting PCa Cells Against Necroptosis 
Understanding of the molecular mechanisms involved in resistance to both 
apoptotic and non-apoptotic cell death pathways is essential for the development of 
innovative therapies and to maximize their clinical potential [1]. Necroptotic 
(programmed necrosis) and necrotic (accidental necrosis) cell death, share the same 
morphological features such as lysosomal membrane permeabilization (LMP) and plasma 
membrane permeabilization, and both can be induced by severe oxidative stress and 
operate in tumor cells [2].  In a normal context, the release of pro-inflammatory signals 
from necrotic/necroptotic cells into the extracellular microenvironment initiates a pro-
inflammatory response that might not be beneficial to healthy tissue [3].  However, in 
cancerous tissue a pro-inflammatory response to necroptotic/necrotic cells could further 
promote tumor development because inflammatory cells are capable of inducing signals 
leading to increase in angiogenesis, cell proliferation, and invasiveness [3].  For example, 
IL6, a cytokine that is released by many types of pro-inflammatory cells, including 
necrotic cells, has been implicated in PCa chemoresistance [4]. 
Work from our laboratory, including data shown in this dissertation, has provided 
evidence that LEDGF/p75 upregulation protect cancer cells against inducers of caspase-
independent cell death, and that this protein needs to stay structurally intact  to exerts its 
protective effects [5-9]. On the other hand, cells treated with the classical apoptosis 
inducers TRAIL (TNF-related apoptosis inducing ligand) or STS (staurosporine), which 
activate caspase-dependent apoptosis, die regardless of the level of expression of this 
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protein [6-7, 9]. The reason is that during apoptosis caspase-3 cleaves LEDGF/p75 into a 
fragment of 65 kD that lacks the pro-survival activity of the intact protein and enhances 
cell death under stress conditions [5-8]. Also, p52, the short alternative splice variant of 
LEDGF/p75 is cleaved by caspase-3 during apoptosis into a p38 fragment that abrogates 
the survival functions of LEDGF/p75 by abolishing its transcriptional activity [8].  
In Chapter 2, Figure 11, we clearly observed cleavage of LEDGF/p75 when PCa 
cells were treated with TRAIL, but minimal or no cleavage when the cells were treated 
with the taxane drugs DTX and CBZ [7].  Consistent with this, we did not observe 
elevated levels of apoptotic cells or processing of caspase-3 into its large and small active 
subunits in cells treated with these taxanes (Chapter 2, Figure 11). However, caspase-3 
activation and cellular apoptotic morphology were clearly observed when PCa cells were 
treated with TRAIL. This was interpreted as that in our specific PCa cellular models the 
taxanes are activating a caspase-independent mode of cell death, thus explaining the 
minimal appearance of apoptotic cleavage fragments of LEDGF/p75 and the fact that this 
protein stays largely intact during taxane treatment.  This could also explain in part why 
the cells are protected when treated with the taxanes, since by remaining structurally 
intact LEDGF/p75 is functionally active.   
These findings are supported by previous observations from our group in which 
DTX treatment induced caspase-independent cell death characterized by LMP and 
cathepsin release in PCa cells treated with DTX, and that enforced overexpression of this 
protein in these cells protected them against DTX [9].  We also showed recently that 
LEDGF/p75 overexpression in PCa cells treated with tert-butyl hydrogen peroxide 
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(TBHP), a stable homologue of hydrogen peroxide widely utilized to induce oxidative 
stress induced-necrosis, was able to attenuate cell death [6].  
If LEDGF/p75 is acting a “guardian of the lysosome” as suggested previously [9-
10], this protein could also be involved in protecting cells against physiological pro-
inflammatory modes of caspase-independent cell death such as necroptosis [2-3].  To test 
this hypothesis, we designed a series of experiments in which we treated the PCa cell 
lines PC3, PC3-DR, DU145, and DU145-DR with the apoptotic inducer TRAIL in the 
presence or absence of the broad caspase-inhibitor zVAD-fmk.  By inactivating TRAIL-
induced caspase-dependent apoptosis with this inhibitor, we primed the cells to activate 
the necroptotic cell death pathway as described previously [11-12]. We pre-treated the 
PCa cells for 2 hours with 20μM zVAD and then treated them with 100ng/ml TRAIL in 
combination with 20μM zVAD. We measured cell viability at 72 hrs and 96 hrs after 
addition of z-VAD to determine if cells could recover from TRAIL-induced apoptosis. 
Our results showed that PC3 cells (low LEDGF/p75 expression) and DTX-resistant PC3-
DR cells (high LEDGF/p75 expression) treated with TRAIL for 72 hrs (Figure 14A) and 
96 hrs (Figure 14B), showed low survival regardless of LEDGF/p75 expression levels. 
However, when we pre-treated cells with the TRAIL/z-VAD combination, we observed a 
slight but significant recovery in cell viability at both 72 hrs and 96 hrs, especially in the 
PC3-DR cells, which have high endogenous levels of LEDGF/p75.  This could be more 
clearly observed at 96 hrs, in which there was a significant recovery in viability in the 
PC3-DR cells treated with TRAIL/zVAD compared to the PC3 cells with the same 
treatment conditions (Figure 14B).   
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Figure 14. Assessment of cell viability as measured by MTT assay in PC3 and PC3-DR 
cells treated with TRAIL or TRAIL with zVAD. PC3 (red bars) and PC3-DR cells (blue 
bars) treated with 100ng/ml TRAIL or 100ng/ml TRAIL with 20uM of zVAD for 72 hrs 
(A) and 96 hrs (B). Statistical significance was determined by comparing the values 
between the groups treated with TRAIL or TRAIL + zVAD and between PC3 and PC3-
DR cells treated with TRAIL + zVAD respectively, using Student’s t-test (*p<0.05).   
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We performed experiments under exactly the same conditions in DU145 and 
DU145DR cells and measured cell viability at 72 hrs (Figure 15A) and 96 hrs (Figure 
15B). Similar to what we observed previously the PC3 and PC3-DR cells, a significant 
recovery in cell viability was observed when DU145 and DU145-DR cells were treated 
with the TRAIL/z-VAD combination, compared to cells treated only with TRAIL.  This 
significant recovery in cell viability was observed at both 72 hrs (Figure 15A) and 96 hrs 
(Figure 15B). However, the recovery was more evident when cells were treated with the 
TRAIL/z-VAD combination at 96 hrs in the DU145-DR cells, which have higher 
endogenous levels of the LEDGF/p75 protein, when compared with DU145 cells treated 
under the same conditions although it was not statistically significant (Figure 15B).    
While we cannot determine from the present data that the protection of the DR 
cells against TRAIL/z-VAD induced necroptosis was due to elevated expression of 
LEDGF/p75 in these cells,  we speculate that upregulation of this protein may contribute 
to protection of PCa cells under conditions in which there is activation of necroptotic-cell 
death.  We induced necroptosis with TRAIL/z-VAD, a combination that has been 
demonstrated to induce necroptosis in cancer cells.  We can infer based on these and 
published data that under drug treatments that fail to effectively activate caspases, thus 
leaving LEDGF/p75 uncleaved by caspases, this protein will remain intact and able to 
exert its cellular protective functions, including chemoresistance.  
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Figure 15. Assessment of cell viability as measured by MTT assay in DU145 and 
DU145-DR cells treated with TRAIL or TRAIL with zVAD.  DU145 (green bars) and 
DU145-DR cells (orange bars) treated with 100ng/ml TRAIL or 100ng/ml TRAIL with 
20uM of zVAD for 72 hrs (A) and 96 hrs (B). Statistical significance was determined by 
comparing the values between the groups treated with TRAIL or TRAIL + zVAD and 
between DU145 and DU145-DR cells treated with TRAIL + zVAD respectively, using 
Student’s t-test (*p<0.05).  
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LEDGF/p75 Overexpression Leads to Resistance to Doxorubicin Treatment 
In the previous chapter, we showed that the DTX resistant PC3-DR and DU145-
DR cells were not only resistant to this drug, but also to the other clinically relevant 
taxanes PTX and CBZ when compared to the drug-senstive PC3 and DU145, 
respectively. When we treated the cells with the classical apoptotic inducer TRAIL they 
were sensitive, as evidenced by the robust apoptosis detected in all cell lines. These 
results suggested that the protection conferred in part by LEDGF/p75 overexpression is 
drug-specific. TRAIL sensitivity was explained by previous studies showing that 
caspase-3 cleaves LEDGF/p75 into a fragment of 65 kD [5].  This fragments does not 
possess the pro-survival activities of the intact protein and even exacerbates cell death 
under stress conditions [5]. We also studied the response of the drug-resistant and –
sensitive cells to another drug, doxorubicin (DOXO). This drug is a member of the 
anthracyclines, a class of drugs capable of intercalating DNA and directly affecting 
transcription and replication [13]. DOXO is not utilized in typical chemotherapeutic 
regimens due to its toxicity.  However, there are reports of the utilization of this drug for 
the treatment of CRPC, although severe toxicity has been reported when used alongside 
an aggressive treatment regime [13]. To determine if our taxane resistant PCa cells were 
also sensitive to DOXO, we treated PC3, PC3-DR, DU145 and DU145-DR with 
increasing concentrations of DOXO and measured cell viability 72 hr after the initial 
exposure.  PC3-DR cells exhibited significantly increased cell viability when compared 
to the PC3 cells at the 500 nM and 1000 nM range (Figure 16A).  DU145-DR cells also 
exhibited increased viability when treated with DOXO, compared to the drug sensitive 
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DU145 cells (Figure 16B).  However, the data for DU145 cells is the average of two 
experiments in triplicates. Additional experiments in this specific range of concentrations 
are necessary with the DU145 and DU145-DR cells to reach statistical significance.  
The data presented in Figure 16 indicate that the DTX-resistant cells, which have 
high LEDGF/p75 expression, are more resistant to DOXO compared to sensitive cells. 
These observations coincide with data by other groups showing that overexpression of 
LEDGF/p75 in MCF-7 cells protected these cells against LMP-inducing agents such as 
siramesine, etoposide,  and DOXO [10].  This is also consistent with the observation that 
osteosarcoma cells depleted of LEDGF/p75 were incapable of effectively repairing DNA 
damage induced by DOXO, implicating this protein in DNA damage repair [14].   
Because of the significance of taxanes in the clinical treatment of PCa, and the minimal 
clinical relevance of DOXO in the treatment of this malignancy, we opted not to continue 
performing experiments using DOXO, and to focus our efforts on studying the effects of 
LEDGF/p75 targeting on the sensitization of DTX-resistant PCa cells to taxanes.  
 
 111 
 
 
 
 
 
 
Figure 16. PC3-DR (A) and DU145-DR (B) cells are resistant to DOXO. Assessment of 
cell viability as measured by MTT assay in PC3 (red triangles),  PC3-DR (crosses), 
DU145 (orange diamonds), and DU145-DR (green squares) cells treated with increasing 
concentrations of DOXO (5nM, 10nM, 50nM,  500nM, and 1000nM) for up to 72 hr. 
Graph A (PC3) represents the average of at least three different experiments in triplicates 
normalized to untreated controls. Graph B (DU145) represents the average of two 
different experiments in triplicates normalized to untreated controls.  Standard error of 
the mean (SEM) was calculated in both graphs. Utilized Student t-test (*p<0.05). 
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Initial Repurposing of HIV-Based Inhibitors to Target LEDGF/p75 in PCa 
The development of cytotoxic drugs and combinatorial regimens have resulted in 
an improved quality of life and prognosis of cancer patients [15]. However, there is still a 
need to develop innovative and targeted therapeutic approaches to circumvent 
chemotherapy resistance [16] As mentioned previously, LEDGF/p75 is a well-established 
cellular co-factor for HIV-1 replication and is currently being extensively studied as a 
druggable target.  The LEDGF/p75–HIV IN interaction or the interaction of LEDGF/p75 
with other oncoproteins in the context of cancer are ideal therapeutic targets since they 
provide new opportunities for the development of small molecule inhibitor (SMI)-based 
treatments [16].  
Recently, SMIs have been developed to disrupt LEDGF/p75-HIV-IN interaction 
resulting in decrease viral replication [17-18]. Its role in HIV infection and relevance in 
cancer makes LEDGF/p75 an attractive therapeutic target in both HIV-AIDS and cancer.  
Inhibitors designed to disrupt LEDGF/p75 interactions with HIV-IN through its IBD can 
also be repurposed or repositioned for cancer treatment because in cancer cells 
LEDGF/p75 interacts with other cancer-related proteins precisely through the IBD.  For 
example, small peptides were demonstrated to effectively disrupt the interaction between 
LEDGF/p75 and the MLL/menin complex in leukemia cells, decreasing MLL-fusion-
mediated transformation [19].  
Our collaborator, Dr. Nouri Neamati (University of Michigan), and his team 
described the design and discovery of novel SMIs that inhibited the interaction between 
LEDGF/p75 and HIV-IN (Figure 17) [20].  
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Figure 17. Disruption of the protein-protein interaction between LEDGF/p75 and HIV-
IN by SMIs (Adapted from Suzuki et al. 2011, Sanchez et al, 2012) [20]. 
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Using LEDGF/p75 IBD-based pharmacophore models, these researchers 
identified acylhydrazones that effectively disrupted this interaction. This class of 
compounds are used to treat tuberculosis and have also been demonstrated to possess 
antiretroviral activity [20]. We started initial studies aimed at evaluating the potential of 
repurposing these SMIs to target LEDGF/p75 in order to sensitize CRPC cells to 
chemotherapy.   
In collaboration with Dr. Neamati, we initially evaluated the cytotoxicity of 
approximately 130 of these acylhydrazones compounds in PC3, PC3-DR without the 
presence of any other drugs in order to identify which ones showed activity or decreased 
cell viability (Figure 18 A-G). We treated the cells with the compounds at 1μM, 5μM and 
10μM and measured cell viability using MTT at 72 hr. For example, compounds 13 and 
14 in Figure 18A, showed robust cytotoxicity in the PC3 cells but showed minimal 
toxicity in the PC3-DR cells. This could be explained by the high endogenous levels of 
LEDGF/p75 in the PC3-DR cells versus in the lower expression in the PC3 cells and the 
ratio of protein/compound.  Perhaps a higher concentration of these compounds might be 
toxic by itself, but since at 10μM they showed activity in the PC3 cells, this was an 
indicator that these compound might be active when combined with DTX.  From this 
initially tested group, we then selected several compounds that showed activity and 
evaluated them in PC3-DR cells in combination with 10 nM of DTX for 72 hrs. 
Our goal was to identify candidate compounds that either showed cytotoxicity 
alone in both sensitive and resistant CRPC cells or that did not show cytotoxicity alone 
but did exhibit cytotoxicity in the chemoresistant cells the presence of 10 nM DTX, 
 115 
which is the maintenance concentration of the drug-resistant cells.  Figure 19 shows 
examples of the type of studies we want to further pursue.  In these experiments we 
treated PC3-DR cells with 10μM of each compound in combination with 10nM DTX, 
and after 72 hrs we assessed cell viability utilizing MTT assay. In these preliminary 
results, SMIs 13, 14 and 80 showed no cytotoxicity in PC3-DR cells when used alone but 
their effects were more dramatic in combination with DTX.   Additional experiments to 
determine the IC50 of these compounds in the presence and absence of DTX, and achieve 
statistical significance, will be performed in studies beyond the scope of this dissertation. 
These experiments will also be expanded to additional PCa cell lines with variable levels 
of LEDGF/p75 such as DU145 and DU145-DR cells, and cell lines with transient and 
stable knockdown of LEDGF/p75.   
To further select the lead SMIs, we compiled data from Sanchez et al. [20], in 
which some of these compounds also showed anticancer activity as determined by their 
IC50 and/or cytotoxicity in HCT116 (colorectal carcinoma) cells (Table 1).  These will 
be the first to be tested but others will be selected considering the previous preliminary 
experiments.  Once our group identifies lead SMIs that exert cytotoxicity in cells 
overexpressing LEDGF/p75, such as the drug-resistant PC3-DR and DU145-DR, in the 
presence of taxanes, then in vitro binding studies will be performed to determine the 
specific binding of these lead SMIs to LEDGF/p75. 
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Figure 18. Initial screening  of SMIs in PC3 and PC3-DR cells. Cells were treated with 
10uM of SMIs to identify candidate compounds that show activity. Viability was 
assessed 72hrs after treatment utilizing MTT.  
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Figure 19. Co-treatment with selected SMI’s and 10nM of DTX. PC3-DR cells were 
treated with 10uM of each compound in combination with 10nM of DTX, their 
maintenance drug concentration. Viability was assessed 72hrs after treatment utilizing 
MTT. Average of three individual experiments in triplicates normalized to untreated 
controls. Standard error of the mean (SEM) was calculated. Utilized student t-test 
(*p<0.05). 
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Table 1. Selected compounds for further studies. Additional data 
obtained from Sanchez et al, 2013 [20].  
Compound Identifier and 
structure  
LEDGF/p75-
IN 
IC50 uM 
HCT116 +/+ 
p53 
IC50 uM  
13 - 31B12 (84) 
En-T5755296 
 
4 ± 2 
 
 
 
 
<1 
91 - EN10K 31C12 
En-T5755298 
 
2 ± 1 
 
 
6 
14 - EN10K 31A13 (89) 
En-T5756746 
 
7 ± 3 
 
 
 
1.5 
82 - EN10K 31A12 
En-T5755295 
 
>50 
 
 
 
<1 
B31E11 (110) T5755287 
 
 
>100 
 
60b1 (118) 
 
23 ± 3 
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Our ultimate goal in these follow-up studies is to identify and characterize a panel 
of lead SMIs that abrogate LEDGF/p75 pro-survival functions in chemoresistant cells in 
the presence of DTX. We hypothesize that these compounds disrupt LEDGF/p75 survival 
functions by binding to its IBD and hindering its interaction with other co-transcription 
factors. This would result in decreased LEDGF/p75-mediated transactivation of survival 
genes.  Studies focused on the functional capabilities of this protein will be performed to 
investigate if the transactivation of target genes, such as Hsp27, is affected.  Follow-up 
studies could also explore if the interaction of LEDGF/p75 with other transcription 
factors or co-activators, such as Menin and MeCP2, is disrupted.  Finally, by studying the 
structure and functional groups of the lead SMIs, in the context of their cytotoxic 
functions, we will be able to identify if certain chemical moieties in these compounds are 
more relevant and show increased activity.  
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CHAPTER FOUR 
OVERALL DISCUSSION 
Prostate cancer (PCa) is the most commonly diagnosed cancer in U.S. males and 
the third leading cause of cancer deaths in this population [1]. CRPC, the advanced form 
of this disease, is characterized by biochemical and radiographic progression despite 
hormonal manipulation, and is associated with poor prognosis [2-3].  Progress in 
understandings the mechanisms leading to CRPC have resulted in the development of 
new therapeutic strategies and regimens, including the anti-androgen drugs abiraterone 
acetate and enzalutamide, the immunotherapeutic vaccine sipuleucel-T, the 
immunotherapeutic antibody denosumab to prevent bone fractures, and the 
chemotherapeutic taxane drugs DTX and CBZ [4]. Despite the different FDA-approved 
therapeutic options, from only DTX in 2004 to six different therapies available in 2016, 
managing CRPC is still challenging due mainly to the limited clinical and survival 
benefits of these treatments caused by primary and acquired resistance [3]. There is an 
urgent unmet need in understanding what would be the most beneficial treatment options 
and combinatorial therapies, and the most appropriate sequence of the therapy 
administration [5]. Another layer of complexity is the heterogeneity in the presentation of 
PCa, from undiagnosed indolent to rapidly spreading and lethal tumors, and the broad 
spectrum in its biological and clinical behavior, even within the same patient [6]. Efforts 
to understand the genomic landscape of PCa and the genomic diversity between localized 
and aggressive metastatic disease, along with the identification of potentially druggable 
aberrations, are still needed to identify potential therapeutic targets [6].  
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In this dissertation research we sought to further establish the role of LEDGF/p75 
in PCa taxane resistance and its potential as a novel therapeutic target for overcoming 
chemoresistance.  As reviewed in the Introduction, research from our group, including 
the published data presented in Chapter 2 (hereafter cited as ref. 18), and others supports 
the role of this emerging stress oncoprotein protein in promoting tumorigenesis and 
tumor aggressive properties, including chemoresistance, in various human cancer types  
[7-17]. While further studies are necessary to completely understand the mechanisms by 
which LEDGF/p75 protects cancer cells against environmental stressors, including 
chemotherapeutic drugs, we have demonstrated that LEDGF/p75 overexpression protects 
cells against caspase-independent cell death caused by strong inducers of oxidative stress 
and LMP such as chemotherapeutic drugs and oxidants  [9, 11].   
We provided evidence in Chapter 2 that the clinically relevant taxane drugs DTX 
and CBZ can activate a caspase-independent mode of cell death, as demonstrated by 
minimal caspase-3 processing, LEDGF/p75 cleavage, and apoptotic morphology in PCa 
cells exposed to these drugs.  Furthermore, our unpublished results in which we treated 
our PCa cells with TRAIL in the presence of the broad caspase-inhibitor zVAD-fmk, 
indicate that LEDGF/p75 overexpression might confer resistance to therapeutic drugs 
under conditions in which caspases are inactivated. These observations are relevant due 
to increasing evidence of the unfolding role of caspase-independent modes of cell death, 
such as necrotic/necroptotic pathways, in the development of drug resistance depending 
on the tumor microenviroment [18]. Efforts during the past decade utilizing single 
pathway anti-apoptotic agents in order to elicit an apoptotic response in cancer cells have 
not been successful. Thus, feasible and successful treatment strategies have to consider 
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the crosstalk between multiple survival networks including survival proteins and other 
modes of cell death [19].  
Previous work from our group demonstrated that LEDGF/p75 overexpression 
attenuated DTX-induced caspase-independent cell death associated with LMP in PC3 
cells [9], but does not protect against caspase-dependent cell death induced by TRAIL or 
STS [9,11].  Our observation of minimal caspase activation and/or activation of a 
caspase-independent pathway by DTX is supported by recent observations from another 
group showing that DTX induced minimal caspase activation in DU145 cells [20]. In 
light of this evidence, we have to consider the possibility that cancer cells treated with 
DTX and CBZ may activate both caspase-dependent and –independent cell death 
mechanisms of in an effort to effectively respond to cytotoxic insults [21-22]. The 
development of resistance to non therapy-specific and therapy-specific insults, including 
activating genes to antagonize a specific mode of cell death, highlights the plasticity of 
cancer cells to adapt to the environmental conditions [3]. 
Although DTX is still the preferred cytotoxic agent utilized for the treatment of 
CRPC, yielding survival benefits, around half of the patients do not respond to this 
therapy, and those who initially respond eventually develop resistance, ultimately 
succumbing to the disease [23]. Resistance to taxanes is not completely understood, but 
evidence points out to tubulin mutations, multidrug transporters, androgen receptor-
mutations, and overexpression of transcription factors and stress proteins such as Stat1, 
Stat3, NF-kB, Hsp27, and Clusterin [23-28]. Also, tumor growth and chemoresistance are 
aided by the disablement of cell death responses and the interplay between 
microenvironmental or intracellular factors that antagonize or promote the different 
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modes of cell deaths, particularly apoptosis, necrosis and autophagy [29]. Whether the 
observed resistance is driven by extrinsic or intrinsic factors, such as the upregulation of 
LEDGF/p75 and other stress oncoproteins, evidence supports the concept that PCa 
progression towards an aggressive state characterized by complete therapy resistance is 
associated with increased molecular aberrations that gives the tumor the advantage to 
circumvent the anti-tumor effects of therapy [6]. Until we fully comprehend how all these 
molecular alterations affect therapeutic outcome, logically the best approach would be to 
simultaneously or sequentially target multiple molecular pathways that maintain 
resistance to both caspase-dependent and –independent cell death.    
For the present studies, we used CRPC cellular models (PC3 and DU145) that 
were treated with increasing concentrations of DTX and selected over time for their 
acquired resistance to this drug. These cells naturally overexpress LEDGF/p75 
endogenously as they acquire this resistance, suggesting that this stress protein may 
contribute to promoting the selection of surviving cells in the presence of DTX.   
Although other mechanisms of resistance and other survival proteins are also likely 
overexpressed in these cells, we were interested in the role of LEDGF/p75 due to 
previous observations from our group linking its enforced overexpression (plasmid-
mediated) to DTX resistance in PCa cells [9].  We observed that as these cells acquired 
resistance to DTX, they also became resistance to the other clinical taxanes, PTX and 
CBZ,  as well as the DNA-intercalating drug DOXO (Chapter 3, Figure 3).  This 
observation is consistent with the clinical observation that patients who develop 
resistance to DTX therapy eventually also develop resistance to other drugs, including 
CBZ [3-5].   Resistance to DOXO and other DNA damaging drugs in cells 
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overexpressing LEDGF/p75 has been previously documented, given the function of this 
protein in DNA damage repair  [8,10,14].  As shown in Chapter 2, both DTX-sensitive 
and -resistant cell lines exhibited robust sensitivity to the apoptosis inducing death ligand 
TRAIL.  This suggests that the cellular protective functions in these cellular models of 
DTX resistance could be drug-specific.  The exquisite sensitivity to apoptosis induced by 
death ligands such as TRAIL in chemoresistant PCa cells could be exploited as a strategy 
to bypass resistance, however the high toxicity of these ligands tempers their clinical 
utility as discussed below.   
LEDGF/p75 appears to be involved in cellular resistance to caspase-independent 
cell death but not to caspase-dependent apoptosis.  This is supported by observations 
from our group and others that overexpression of this protein protects cells against 
taxane-induced, caspase-independent cell death associated with LMP, and also against 
oxidative-stress induced necrosis induced by TBHP [9, 11].  As we demonstrated in our 
studies, PCa cells overexpressing LEDGF/p75 did not appear to be resistant to the 
classical apoptotic inducers TRAIL or STS regardless of the levels of this protein [9, 10, 
11]. These observations are concurrent with other studies from our laboratory that 
showed that during caspase-dependent cell death, caspase-3 cleaves LEDGF/p75 into a 
fragment of 65kD that lacks the pro-survival activity of the intact fragment and  enhances 
cellular death under conditions of stress [7, 11].  Also, when the short alternative splice 
variant of LEDGF/p75, p52, was cleaved by caspase-3, it abrogated the survival 
functions of LEDGF/p75 by abolishing its transcriptional activity [30]. Thus, we can 
reach the conclusion that LEDGF/p75 is not a classical anti-apoptotic protein such as 
Survivin, Bcl-2, and Clusterin, which directly inhibit intracellular processes associated 
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with apoptosis, but rather an inhibitor of stress-induced cell death involving LMP such as 
necrotic cell death. However, it is plausible that LEDGF/p75 could promote protection 
against apoptosis if this mode of cell death occurs downstream of events antagonized by 
this protein such as DNA damage and LMP [9, 10, 14]  
In agreement with this conclusion, we also showed that in conditions in which the 
cells are primed to undergo necroptosis [31-33], drug-resistant PCa cells, which have 
high endogenous levels of LEDGF/p75, are more resistant to TRAIL-induced cell death 
in the absence of caspases than the drug sensitive cells. These observations further 
implicate LEDGF/p75 in resistance against caspase-independent cell death, possibly 
necroptosis, although this possibility needs to be further explored. Necroptosis is a 
recently described regulated form of programmed necrosis mediated by receptor 
interacting protein kinases 1 and 3 (RIPK1 and RIPK3) and its substrate mixed lineage 
kinase like (MLKL) [31]. Phosphorylation and trimerization of RIPK1,3 in the absence of 
caspase activation leads to phosphorylation of MLKL, which in turn oligomerizes in the 
plasma membrane, leading to its permeabilization, LMP, and cytoplasmic destruction 
[34]. Evidence supports that necroptosis could have a pro-inflammatory function by 
acting as an initiation signal and contributing to the amplification of signaling leading to 
production of cytokines [35]. By inhibiting necroptosis, perhaps by protecting oxidative 
damage to lysosomal membranes, LEDGF/p75 might be able to reduce this inflammatory 
response and subsequent tissue damage.  However, in order to unambiguosly demonstrate 
a role for LEDGF/p75 in PCa cell resistance to drug-induced necroptosis, additional 
studies will be necessary utilizing specific necroptosis inhibitors such as necrostatin 
(Nec-1, a RIPK1 inhibitor), GSKs (RIPK3 inhibitors), and Necrosulfanomide (MLKL 
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inhibitor), in cells with and without LEDGF/p75 overexpression and in the presence or 
absence of combinations of z-VAD with different antitumor drugs such as taxanes, 
TRAIL, doxorubicin, etc. The high complexity and labor intensive nature of these 
additional studies merits a systematic and comprehensive analysis that is beyond the 
scope of this dissertation.   
If LEDGF/p75 contributes to selective drug resistance and is inactivated by 
caspases in PCa and other cancer types, then induction of tumor cell apoptosis via death 
receptors could be used to bypass the pro-survival activity of LEDGF/p75 and other 
similar survival proteins.  The induction of apoptosis is a therapeutic approach currently 
being studied since mutation rates in the apoptotic receptors are low, suggesting that the 
apoptotic machinery in tumor cells is relatively intact [36]. This could be used as an 
advantage to target these cells.  However, it needs to be recognized that in spite of the 
broad knowledge on mechanisms of apoptosis generated during the past three decades,  
we are still lacking effective anti-cancer therapies targeting tumor apoptosis.  Efforts to 
target the extrinsic – i.e. death receptor-mediated- apoptotic pathways have focused on 
agents targeting the death receptors TRAIL-R1 and TRAIL-R2 because these receptors 
are more prevalent in cancerous cells than in normal cells [36]. However, reports have 
also found high levels of these receptors in normal cell types such as hepatocytes, brain 
tissue and keratinocytes [36].  This could attenuate the clinical effectiveness of targeting 
these receptors. For example, a recent clinical trial in which a TRAIL-R2 agonist 
(TAS266) was used reported adverse effects due to hepatotoxicity [37]. This raises 
concern for the safety of these types of drugs targeting receptors that play a critical role in 
normal tissues due to the possibility of high toxicity to the patient.  Therefore, other 
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therapeutic options targeting molecular pathways that are critical for tumor growth but 
not necessarily for normal tissue growth and function have to be explored in order to 
circumvent therapy resistance.   
As mentioned previously, in addition to its role in cancer chemoresistance, 
LEDGF/p75 plays a pivotal role in facilitating HIV-1 integration and replication through 
its C-terminal integrase binding domain (IBD) [38].  Considering the therapeutic 
potential of disrupting its protein-protein interactions and the pro-survival functions of 
LEDGF/p75, which are largely dependent on the structural integrity of the IBD, various 
studies aimed at targeting this protein have demonstrated that it is a druggable target [38-
42]. For instance, studies from other laboratories have demonstrated that targeting 
LEDGF/p75 decreased tumorigenic potential in DU145 cells [13, 14], and sensitized 
cancer cells (non-PCa) to non-taxane drugs [14], implicating LEDGF/p75 as a contributor 
in the development of chemotherapy resistance. Importantly, LEDGF/p75 does not 
appear to be essential for normal cellular viability since PSIP1/LEDGF/p75-\- knockout 
mice were viable despite suffering multiple developmental skeletal malformations that 
led to an increase in perinatal mortality [43].  In addition, cell lines with stable 
knockdown of LEDGF/p75 have been effectively developed [44-46] albeit with the 
caveat that they have been selected from a surviving pool derived from a larger 
population and have likely developed compensatory mechanisms to survive in the 
absence of this protein.  Taken together, however, these observations validate 
LEDGF/p75 as a potential therapeutic target in diseases in which this protein play a 
critical role such as HIV-AIDS and cancer. 
If LEDGF/p75 is upregulated during the development of taxane chemoresistance, 
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the reasoning is that targeting this protein in pre-clinical models of CRPC would sensitize 
the chemoresistant cells when treated in combination with chemotherapy. Towards this 
goal, we showed that transient depletion LEDGF/p75 reduced the clonogenic potential of 
both sensitive and chemoresistant PC3 and DU145 cell lines, results consistent with 
previous observations [10, 13-14]. We also observed that targeting LEDGF/p75 with 
siRNA in combination with DTX or CBZ treatment significantly reduced the 
clonogenicity of both DU145-DR and PC3-DR cells, with LEDGF/p75 knockdown 
sensitizing the DU145-DR cells more robustly than PC3-DR cells.  This would be 
consistent with previous studies that showed that LEDGF/p75 silencing abrogated 
aggressive properties in DU145 cells [13]. As previously mentioned, we could not 
effectively compare the EC50 values of LEDGF/p75 knockdown alone versus 
knockdown in combination with taxanes due to the limitations in the drug range 
concentrations selected for these experiments.   Moreover, as discussed in Chapter 2, 
synergism between the effects of LEDGF/p75 knockdown alone and knockdown plus 
taxanes could not be calculated because such studies would required a broad range of 
concentrations for both treatments, which cannot be achieved with protein knockdown.   
However, our results provide “proof of principle” for the concept that targeting 
LEDGF/p75 in combination with taxanes could be a promising strategy for 
circumventing chemoresistance in CRPC.   
In our studies we also initiated the evaluation of SMIs previously identified by 
our collaborators [40] to target the interaction between HIV-IN and LEDGF/p75 for their 
potential to target LEDGF/p75 and produce cytotoxicity and overcoming 
chemoresistance in PCa cells. In these initial studies we were able to identify candidate 
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SMIs that exhibited cytotoxicity in PCa cells when used alone or in combination with 
DTX.  We hypothesize that some of these SMIs might be binding to the IBD-domain of 
LEDGF/p75, causing hindrance and possibly disrupting protein-protein interactions with 
other co-transcription factors that are essential for the transcriptional and survival 
functions of this protein.    We anticipate that these initials studies will be expanded to 
identify a few candidate LEDGF/p75 inhibitory compounds that show promise for 
circumventing taxane resistance in pre-clinical models of CRPC.  
Although we focused this dissertation work on the role and targeting of 
LEDGF/p75 in the context of PCa chemoresistance, we also have to consider the 
interplay between multiple, different survival pathways contributing to chemoresistance 
since LEDGF/p75 silencing did not completely sensitize resistant PCa cells to DTX and 
CBZ [Chapter 2] .  The identification of these pathways in cellular models and in patient-
derived biospecimens will facilitate the identification of patients that will response to 
therapy, avoiding unnecessary exposure to cytotoxic drugs [21]. We have to consider in 
our experimental context the contribution of other pro-survival proteins implicated in 
chemoresistance, including Clusterin, heat shock proteins, multi-drug resistance proteins, 
inhibitors of apoptosis, etc. [23, 28, 47-49]. Current studies in our laboratory seek to 
simultaneously target LEDGF/p75 and Clusterin to re-sensitize PC3-DR and DU145-DR 
cells to DTX.  
Another candidate protein for such combinatorial targeting is P-glycoprotein (P-
gp), a multi-drug resistance protein and drug transporter that is weakly expressed in 
normal prostate, but is highly expressed in primary PCa cells and tumor epithelium and 
has been associated with tumor stage and grade [50]. In our studies we asked the question 
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of whether LEDGF/p75 depletion affected the expression of P-gp in our taxane-resistant 
PCa cells.  This was prompted by the possibility that LEDGF/p75, acting as a 
transcription co-activator, could promote the upregulation of P-gp in chemoresistant cells. 
However, our results indicate that these protein act independently of each other in our 
chemoresistant cell models since knockdown of LEDGF/p75 did not affect the expression 
levels of this drug transporter. However, we cannot rule out that P-gp is still regulated by 
LEDGF/p75 at the transcriptional level but its protein stability is not affected by 
LEDGF/p75 depletion. Alternatively, we could conclude that PCa cells develop 
redundancy in their pro-survival and chemoresistance pathways as a strategy to survive 
against different stressors in specific microenvironmental contexts. For instance, a 
previous study demonstrated that although P-gp is upregulated in several chemoresistant 
PCa cells lines, its knockdown only reverses the resistant phenotype in a cell-line 
dependent manner [51].  Although P-gp is an attractive therapeutic target, targeting of 
this drug transporter has not been clinically successful due to adverse side effects, 
toxicity, and altered pharmacokinetics encountered in the studies [51].  The reason for 
this is that P-gp, like TRAIL receptors, plays important physiological roles in normal 
cells that when abrogated with inhibitors cause negative side effects in patients [51].   
Finally, we also observed marginal caspase-3 processing and LEDGF/p75 
cleavage in PCa cells (both sensitive and chemoresistant) treated with DTX and CBZ at 
relatively high pharmacological plasma concentrations that we documented induced cell 
death.  Previous observations from our laboratory and another group also demonstrated 
that caspase-3 activity or LEDGF/p75 cleavage could be induced in PC3 and DU145 
cells, albeit not very robust, at micromolar concentrations of DTX [9, 13].  Taken 
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together, these findings suggest that in addition to apoptosis, other mechanisms of cell 
death that are activated during taxane treatment could result in the development of 
resistance since pro-survival proteins such as LEDGF/p75 may preserve their structural 
integrity in non-apoptotic cell death modalities and protect against drug treatment if 
overexpressed in the tumors.  
 
Conclusions 
The development of redundancy in chemoresistance pathways, likely through 
activation of multiple survival proteins and molecular pathways that antagonize various 
modes of tumor cell death, presents a serious two-prong challenge in the clinical 
treatment of advanced PCa tumors and other tumors: 1) the multiplicity of pathways that 
will need to be targeted to circumvent the resistance, and 2) the toxicity that could be 
developed by patients after targeting some of these pathways in clinical trials.  In spite of 
these challenges, and considering the results from the present study and previous studies 
from our group and other investigators on LEDGF/p75, we believe that co-targeting of 
multiple proteins that are not very critical for the function of normal cells and tissues but 
that are overexpressed in chemoresistant tumors and that protect tumor cells against both 
caspase-dependent and caspase-independent cell death, is a promising and effective 
strategy to overcome taxane resistance in CRPC.   We propose that LEDGF/p75 could be 
one of these proteins and a novel therapeutic target in chemoresistant CRPC.  Future 
studies on establishing LEDGF/p75 as a PCa therapeutic target will need to be focused on 
establishing the role of this protein in promoting other characteristics of prostate 
tumorigenesis such as tumor growth, proliferation, invasiveness, angiogenesis, epithelial 
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to mesenchymal transition, metastasis to bone, etc. Considering the fact that LEDGF/p75 
may not be essential for cell survival under normal conditions, but plays a role in the 
development and maintenance of chemoresistance, it would be important to establish if 
this protein is overexpressed as a result of the stressful microenvironmental conditions 
inside the developing prostate tumor or as a response to the increased endogenous ROS 
accumulation in tumor cells when patients are treated with chemotherapy.  The latest 
possibility is considerably worrisome because of its implications for the development of 
highly aggressive disease as a result of chemotherapy.  Hence, detailed studies 
elucidating the functions, targets, and interacting partners of LEDGF/p75 in CRPC are 
still necessary to fully understand the functions of this stress oncoprotein and the 
mechanisms by which it promotes PCa chemoresistance. This will be critical in the 
development of appropriate therapeutic options for chemoresistance PCa involving 
targeting LEDGF/p75.  
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CHAPTER FIVE 
METHODOLOGY  
The contents of this chapter are for the purpose of instructing current and future 
laboratory members on the methodology utilized in this project. This section will provide 
key details and insights that are important to reproduce the studies presented in this 
dissertation and to troubleshoot common problems that could be encountered in follow up 
studies.   
 
Developing DTX-Resistant Cell Lines 
The metastatic PCa cell lines DU145 (brain metastasis) and PC3 (bone 
metastasis) were purchased from the American Type Culture Collection (ATCC) (Cat.# 
HTB-81 and Cat.# CRL-1435, respectively). Cells were immediately stored in liquid 
nitrogen upon arrival until they were ready to be cultured. These were cultured carefully 
following supplier’s instructions in RPMI medium (Life Technologies – Thermo Fisher 
Scientific) supplemented with 10% fetal bovine serum (FBS), penicillin/streptomycin, 
and gentamicin. Our media is also supplemented with the addition of the reagent 
Normocin (Invivogen) to ensure broad antibacterial protection, including mycoplasma.  
Cells were maintained in a humidified incubator with 5% CO2 at 37°C. It is 
recommended that after cells have been passaged 4 times, the protein levels of 
LEDGF/p75 are examined by immunoblotting. Our group has previously demostrated 
that these have significantly lower levels of LEDGF/p75 than the drug-resistant variants 
[1]. To ensure the quality and reproducibility of the data derived from future studies, 
LEDGF/p75 protein levels should be tested after each batch of cells, both sensitive and 
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resistant, is thawed and re-grown for a few days.   This is important because stressed drug 
sensitive cells may upregulate LEDGF/p75 levels, minimizing the effects of the drug 
resistant cells in comparison studies.   
To ensure quality and viability, cells are collected and frozen when the passage 
number was low or less than 5 passages. The DTX-resistant cell line variants were 
developed as described previously by Patterson et al, 2006 [2], but with a few 
modifications. Briefly, DU145 and PC3 were cultured with the normal medium 
supplementation but with the addition of 1 nM DTX.  The surviving cells were passaged 
four times before increasing the concentration of DTX.  The culture flasks have to be at 
least 70% re-populated by the surviving cells before they are split and exposed to with 
increased DTX concentrations.  If the cell mortality rate is too high and there are only a 
few cells left, these can be re-cultured in a small plate or flask. This allows the cells to 
have important cell-cell contacts that will enable them to grow and multiply. The media 
should be changed every 48 hours even if the flask is not confluent, to ensure that the 
cells are properly supplemented with nutrients and DTX.  The concentration of DTX was 
then sequentially increased to 2nM, 4nM, 6nM and finally to 10nM. This is a variation 
from the original protocol in which the cells were initially treated with 1nM and then 
with 5.5nM. We found that this drastic increase in the DTX concentration was too harsh 
on the cells.  It was more logical and practical to gradually increase the concentration of 
DTX in increments of 2nM. This was then repeated until only the cells with the resistant 
phenotype were selected and could be maintained with minimal cell death in media 
containing 10 nM DTX.  It is important to assess microscopically the morphology of the 
cells before and after each increment in DTX concentration, because the drug-resistant 
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cells have a distinct morphology. They are bigger, rounder, and more multinucleated than 
the parental, drug-sensitive cells. They also have higher messenger and protein levels of 
stress proteins such as LEDGF/p75, Clusterin, and P-gp. To ensure that the cells maintain 
this resistant phenotype, they should be grown in the maintenance concentration of 10nM 
of DTX, and the levels of LEDGF/p75 and Clusterin should be tested after each batch is 
re-grown.    
 
Treatment With Different Drugs and Reagents  
In our experiments, PCa cells were treated with the different cytotoxic drugs at 
increasing concentrations for up to 72 hr, or with 100 ng/ml TRAIL plus Actinomycin D 
for up to 24 hr.  The efficiency of TRAIL in inducing apoptosis is enhanced in the 
presence of a transcription inhibitor such as Actinomicyn D or a protein synthesis 
inhibitor such as cycloheximide.  To ensure reproducibility and efficiency, drugs should 
be handled following the instructions given by the manufacturer. For example, to prepare 
10nM DTX, dissolve the drug in solid form in the vehicle agent DMSO. It is important to 
know what solvent to use to dissolve each drug considering their solubility properties.  
The solubility of DTX in DMSO is 200mg/ml. The molecular weight of DTX is 807.88. 
To prepare 10ml of a 10mM stock, dissolve 80.788 mg in 10ml of DMSO. Divide in 
aliquots of 1ml and freeze the aliquots not in use to ensure stability. It is important to 
dilute each drug in serial dilutions to maintain proportion of drug to media and equal 
distribution of particulate.  
The following cytotoxic drugs were obtained from these companies:  DTX (LC-
Laboratories, cat# D-1000), PTX (Sigma-Aldrich, cat # 33069-62-4 ), DOXO (Sigma-
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Aldrich, cat # 25316-40-9) and CBZ (Sanofi-Aventis, provided by collaborator). TNF-
related apoptosis inducing ligand (TRAIL) was purchased from Peprotech and 
Actinomycin D was purchased from R&D Systems. The broad caspase inhibitor z-VAD-
fmk was obtained from Enzo Life Sciences.  Necrostatin, a RIP-3 inhibitor, and 
Necrosuldamide, a MLKL inhibitor, were obtained from Sigma-Aldrich (cat # N9037-
10MG) and Millipore (cat# 480073-25MG) respectively. 
Since the experiments in which we induced cell death in the presence and absence 
of inhibitors of apoptosis and necroptosis were not part of our published work, the stock 
and effective concentrations were as follows:  
• Broad caspase inhibitor zVAD-fmk: Stock 20mM and effective 
concentrations of 10μM and 20μM. Pre-treat cells for 1 hour before 
adding other drugs. 
• Necrostatin: Stock 20mM and effective concentration of 30μM. Pre-treat 
for 1 hour. 
• Necrosulfonamide: Stock 10mM and effective concentration of 10μM. 
Pre-treat for 2 hours. 
 
Assessment of Cell Viability 
Cell morphology was visualized on an Olympus IX70 microscope equipped with 
Hoffmann Modulation Contrast (Olympus American) and a digital Spot Imaging System 
(Diagnostic Instruments). To assess viability, cells were seeded in 96-well plates at a 
density of 1x104 cells per well and then treated with each individual drug in at least 
triplicates. A modified 3-(4,5-dimethylthiazol- 2-yl)-2,5- diphenyltetrazolium bromide 
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(MTT) assay (Sigma-Aldrich) was performed as described previously by Mediavilla et al, 
2009 [3]. Briefly, 5mg of MTT reagent were dissolved per 1ml of PBS, to a final 
concentration of 200mg of MTT reagent to 20ml of PBS. The suspension needs to be 
vortexed until all solid is dissolved. Since this reagent is light-sensitive, experiments were 
performed in the tissue-culture hood with the lights off and the tube containing the MTT 
reagent was protected with foil. Then, we added 25μl of MTT suspension to each well in 
a 96-well plate where cells are growing in monolayer followed by incubation at 37°C in 
the tissue culture incubator for 2 hrs. After incubation, plates were spinned at 4000 rpm 
for 5 minutes to keep the cells attached to the bottom of the plate. This modification to 
the MTT protocol was done on all assays involving taxanes since these agents are 
microtubule-stabilizing drugs, causing cells to round-up and lose their attachment to the 
plate surface even if when they are still viable.  Then, media containing MTT was 
discarded carefully by flicking the plate first on the sink and then carefully on napkin. 
Media aspiration can also be done, but it must be done carefully since the cells could 
detach from the surface. We then added 300μl of DMSO to each well using a multi-
pipettor and rocked for about 10 minutes until the MTT formazan substrate was 
dissolved. Absorbance was measured at 450 nm using a μQuant microplate reader (Bio-
tek Instruments) or a SpectraMax reader. Values were normalized to the absorbance 
obtained for the untreated control cells. The approximate drug half-maximal effective 
concentration (EC50) was determined using the plotted values of the dose response 
curve.  Each value represented the mean value of at least three different independent 
experiments performed in at least triplicate samples. The standard error of the mean 
(SEM) was calculated for each value. 
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Immunoblotting Procedures 
The following commercially acquired antibodies were used in our studies: rabbit 
polyclonal anti-LEDGF/p75 (1:1000, Bethyl Laboratories Inc. catalog# A300-848A); 
rabbit monoclonal anti-β-actin (1:5000, Cell Signaling catalog # 5125); rabbit polyclonal 
anti-cleaved caspase-3 (1:1000, Cell Signaling catalog # 9661); rabbit monoclonal anti- 
P-gp/MDR1/ABCB1 (1:1000, Cell Signaling catalog # 13342) and horseradish 
peroxidase (HRP)-labeled secondary IgG antibodies (goat anti-rabbit IgG, 1:5000, 
Thermo Fisher Scientific catalog # 31466; goat anti- human IgG/IgA/IgM, 1:5000, 
Thermo Fisher Scientific catalog # A18847). The human serum autoantibody to 
LEDGF/p75 (initially diluted at 1:200 but could be used at higher dilution depending on 
titer) was from the serum bank of the Casiano Laboratory at the Center for Health 
Disparities and Molecular Medicine at Loma Linda University School of Medicine. 
Whole cell lysates were prepared as follows. To collect cells, we detached them 
from the surface of tissue culture flasks or plates using 200μl of trypsin or by adding 1ml 
of PBS and scraping the cells with cell scraper.  Cell suspensions were collected in 5 ml 
plastic tissue culture tubes and stored in ice.  We then spinned the cells for 1 minute in a 
clinical centrifuge at 4,000rpm, discarded the supernatant carefully, and washed the pellet 
with PBS by additional centrifugations.  This step was repeated 3 times to eliminate any 
residual trypsin and media.  This is important because albumin is highly abundant in 
medium and may interfere with electrophoresis and immunoblotting if not adequately 
removed.   We dissolved the pellet in Laemmli sample buffer containing a protease 
inhibitor cocktail (LSB:CPI, volume depends on size of pellet but typically we started 
with 100μl of this reagent for cells collected from two 6-well plates seeded at 120,000 
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cells per well).  Cells were sonicated on ice to disrupt cellular structures. The lysates 
were stored at -80oC for up to 1 year to preserve protein integrity.  
Immunoblotting was performed following this procedure.  Equal amounts of 
protein from whole cell lysates were loaded into individual wells of gels (SDS-PAGE, 
NuPAGE).  Depending on the proteins to be separated we used a variety of gels, such as 
4-12% (most commonly used) and 4-20% polyacrylamide gradient gels, or fixed 10% 
and 12% polyacrylamide gels.  The latter have a 4% stacking gel, which allows for 
sharper protein bands as they enter the 10% or 12% separating gels.   All gels were 
obtained from Thermo Fisher Scientific (previously Invitrogen and then Life 
Technologies).  Protein concentration was determined utilizing the DC protein assay kit 
from BioRad following the manufacturers instructions.  To observe and compare changes 
in protein expression between cell lines, only 5μg-10μg should be loaded onto wells to 
avoid saturating the chemiluminescence signal in immunoblots. For other applications, 
20μg to 40μg is ideal but the sensitivity of the antibody should also be considered.  
Proteins were separated by SDS- PAGE and transferred into polyvinyl difluoride (PVDF) 
membranes (Millipore) in a NuPAGE electrophoresis system by Thermo Fisher 
Scientific. To prepare the samples after calculating the desired protein concentration, we 
diluted the appropriate protein volume in 2.5μl NuPAGE LDS sample buffer (4X) and 
1μl of NuPAGE reducing agent (10X). Final volume, typically 10μl, was achieved 
utilizing deonized water.  
The buffers utilized were purchased from the manufacturer. The protein 
separation was done in MOPS SDS running buffer for 60 minutes at 175 volts. The 
protein transfer was done in transfer buffer diluted to a concentration of 1X (the buffer 
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comes in a 20X concentration) with 10% methanol and 1ml of antioxidant for 90 minutes 
at 25 volts.    
Membranes were blocked in 5% dry milk or 5% Bovine Serum Albumin (BSA), 
depending on the primary antibody, prepared in TBS-T buffer (20 mM Tris- HCl, pH 7.6, 
140 mM NaCl, 0.1% Tween 20). Tipically, we blocked for 2 hours when utilizing 
commercial antibodies. Blocking was done rocking slowly in the cold room. Membranes 
were then probed individually with primary and corresponding secondary antibodies and 
washed 3 times for 10 minutes with TBS-T between each antibody application. The 
incubation time varies between antibodies and should be done following manufacturer’s 
instructions. When utilizing a rabbit anti-LEDGF/p75 antibody by the company Bethyl 
(cat#: A300-848A), we incubated with primary antibody at a 1:1000 dilution overnight 
rocking in the cold room. We then washed with TBS-T 3 times, changing TBS-T every 
10 minutes.  Then, we applied the appropriate secondary antibody for 2 hours in a wet 
chamber. After incubation, we repeated the washing cycles. 
It is important to follow the approved safety protocol when using human sera to 
probe membranes. First, protective goggles, gloves, and lab coat must be worn at all 
times. Protective and absorbent cover should be placed over the bench to ensure that if 
any serum is spilled, it does not contaminate the work area. Pipet tips that were used to 
pipet human serum should be place in a container with bleach to de-contaminate them 
before discarding in approved container. 
We preferably thawed human sera by placing the tubes in ice a few hours before 
use.  If sera must be thaw immediately, put the tube in water bath but return to ice 
immediately after thawing.  If possible, aliquot serum samples to minimize thawing and 
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freezing cycles, which may inactivate serum autoantibodies and other proteins. Serum 
reactivity will vary from vial to vial depending on the titer of the autoantibodies present. 
If the autoantibody titer is high or if the vial has been thawed and frozen multiple times, 
you might get excessive “background” in the chemiluminescence signals, which will 
impede the visualization of the protein bands.  To minimize this, we blocked the 
membranes to be exposed to human serum in TBS-T with 0.1% Tween and 5% milk for 2 
hours.  Albumin was not used in blocking solution when human sera was used due to the 
presence of anti-albumin autoantibodies in human serum, which will increase the 
background signal.   We applied primary human serum autoantibody at a 1:200 dilution 
in TBS-T with 5% milk (serum dilution depends on the titer of the particular 
autoantibody) to the membranes placed on top of paraffin in a wet-chamber for 2 hrs.  
This was done to use the minimum amount of serum possible for those sera available in 
limited volumes.  Alternatively, for high titer autoantibodies for which we had large 
serum volumes, membranes were placed in small plastic trays and incubated at room 
temperature with the diluted serum in a rocking platform, with the rocking at the lowest 
setting possible to minimize background formation.  After primary serum antibody 
application, the membrane was washed at least 5-7 times, changing media every 10 
minutes, and placed in a wash plastic tray in the rocking platform, with minimum 
rocking.  For each wash, we held the membrane with tweezers and washed it (both sides) 
from top to bottom with TBS-T (no milk) following a zig-zag pattern using a wash bottle 
with spout.  We then incubated the membrane with appropriate secondary HRP-labeled 
rabbit- or goat-anti-human antibody at a 1:1000 dilution (TBS-T with 5% milk) for 1-2 
hours in the wet chamber or plastic tray. Again, we washed at least 5-7 times, changing 
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media every 10 minutes, rocking at the lowest setting.  
Enhanced chemiluminescence (ECL) was used to detect immunoreactive protein 
bands.  For this, the ECL Western Blotting Substrate (Thermo Fisher Scientific Pierce, 
catalog # 32106) was added to the antibody-protein surface of each PVDF membrane, 
followed by incubation for 5 minutes. Membranes were then transferred to 
autoradiography cassettes and exposed to autoradiography films for different lengths of 
time to ensure accurate detection of immunoreactive protein bands. 
 
Indirect Immunofluorescence Microscopy 
To visualize endogenous LEDGF/p75 expression, PCa cells were grown as 
monolayer in chamber slides until they reached a confluency of 70%. The media was 
carefully aspirated and cells were then washed twice with PBS by carefully spraying at a 
corner of the chamber wells with a wash bottle with spout and aspirating the liquid 
without touching the cells.  Cells where then fixed with 4% formaldehyde for 20 minutes 
and permeabilized with 0.5% Triton X-100 for 10 minutes.  Cells were then incubated 
with human anti-LEDGF/p75 serum autoantibody at 1:200 dilution for 1 hr in a humid 
chamber. After washes with PBS, cells were incubated with an FITC-conjugated goat 
anti-human IgG (H+L) secondary antibody (1:200, Thermo Fisher Scientific catalog # 
62-7111), used at 1:200 dilution. Chamber wells were removed carefully, including any 
residual glue, with tweezers.  Cells were counterstained with medium containing 4’,6-
diamidino-2- phenylindole (DAPI) and an anti-fade (Vectashield), and a coverslip was 
then carefully placed over the cells. To remove excess medium and bubbles, we placed a 
kim-wipe on top of the coverslip and pressed carefully from the top avoiding lateral 
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movements to prevent dislodging the cell monolayer.   As an alternative to chamber 
slides some experiments were conducted in commercially available ANA slides (acquired 
as a kit from Inova Diagnostics), which already have HEp-2 (HeLa derivative) cells 
grown in monolayer and fixed/permeabilized in individual wells.   The procedures were 
similar but followed the specifications of the manufacturer. 
Images were acquired in a BioRevo Keyence BZ-9000 fluorescent microscope 
(Keyence).  Alternatively, high-resolution images can be acquired using a confocal 
microscope at the LLU Advanced Imaging Facility.  It is critical that all images 
corresponding to a particular antibody and fluorescent probe should be obtained using the 
same parameters, particularly if expression levels of the protein of interest are been 
assessed in different cell lines or under different treatments or conditions.     
 
RNA Interference-Mediated Knockdown of LEDGF/p75 in PCa Cells 
To achieve transient knockdown of LEDGF/p75 in our cellular models, the si-
LEDGF/p75 sequence corresponded to nucleotide sequence 1340–1360 (‘5-AGACAGC 
AUGAGGAAGCGAdTdT-3’), present in a C-terminal region of LEDGF/p75 that is not 
shared by its short alternative splice variant LEDGF/p52.  This was critical to ensure 
specific knockdown of LEDGF/p75, leaving LEDGF/p52 intact.  Cells were transfected 
with 100nM siRNAs or up to 500nM depending on endogenous LEDGF/p75 levels, 
using oligofectamine (Life Technologies) following manufacturer’s instructions. A 
scrambled siRNA duplex (siSD, Dharmacon) was used as a negative control at a 
concentration of 50nM.  To seed the cells we used antibiotic free media, which ensure 
that antibiotics do not interfere with the uptake of the siRNA oligos. We also prepared the 
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oligofectamine-siRNA complexes in serum free media since serum interferes with the 
formation of these complexes.  Based on our experience [1], LEDGF/p75 levels remain 
depleted for up to 96 hrs, after transfection as determined by immunoblotting, however, 
this may vary depending on the growth rate of the particular cell line used in the 
experiment.     
 
Clonogenic Assays 
Cells with and without LEDGF/p75 knockdown were cultured at a density of 
1x103 cells per well in 6-well plates and treated with increasing concentrations of drugs 
as described previously.  Since 1x103 per well is a relatively small number of cells and 
consequently there may be problems with attachment due to lack of cell-cell contact, it is 
important to remove all residual trypsin by washing the cells 2-3 times with PBS after 
trypsinization.  For this, we collected cells in a 5ml tube, centrifuged them at 4,000rpm 
for 2 minutes, and discarded the supernatant. We resuspended the cells gently in 2-5ml of 
media to make sure that the final volume of the cell supension to be added to each well 
was not less than 1μl. This final volume depends on the number of live cells per ml in 
your cell suspension. This must be used to calculate the volume of cells to be seeded in a 
final volume of 2 ml of media per well in 6-well plates. Also, we treated the plated cells 
with each drug when they were already fully attached to the bottom surface of the wells 
and not round.  Thus, we waited at least overnight to ensure proper cell attachment.  
 Cells were grown for 12 days, which is typically when the surviving colonies 
were visible.  After removing the media, the colonies were washed with PBS by gently 
swirling or rocking for 5 minutes with enough PBS to cover the wells. We then added  
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are 1ml of fixing solution (3:1 methanol:acetic acid) to each well and rocked or swirled 
for 20 minutes.  The fixing solution was carefully aspirated and colonies were gently 
washed twice with PBS.  Colonies were stained with 0.5% crystal violet diluted in 
methanol for 10 minutes. Finally, crystal violet solution was removed by washing with 
double distilled water in a sink (carefully without directly spraying the colonies). Plates 
were inverted on top of paper towel and dried overnight. 
 Images of each individual plate were acquired using the VisionWorks 
Acquisition and Analysis software in a GelDoc-It2 imager (UVP, Analytik Jena 
Company).  The Automated Colony Counting capability of the software was used to 
count each colony in the individual wells using the same parameters for each plate. At 
least three plates from three independent experiments were used for quantification of 
colonies under a particular experimental condition or treatment. In addition to number of 
colonies, we should also consider changes in colony size as a parameter of cellular 
proliferation in response to drug treatments.  
 
 
Statistical Analyses 
The Student’s t-test (paired, two-tailed) was used to evaluate differences between 
treatment and control groups using Microsoft Excel.  Differences were considered 
statistically significant at P values equal or below 0.05. As a side note, a paired student T-
test should not be used when comparing multiple parameters due to the introduction of 
significant errors. For this, use a two-tailed t-test or another statistical method considering 
each of their assumptions.   
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 Additional protocols and experimental details can be found in the laboratory 
notebook and page numbers as indicated in Table 2 below. These notebooks are stored in 
the Casiano Laboratory, located in the first floor of Mortensen Hall in Loma Linda 
University, Loma Linda CA.   All electronic files pertaining this dissertation work are 
stored in the Casiano laboratory computers and the Casiano Laboratory external drive 
memory under the folder Leslimar Rios Colon Casiano Lab Files 
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Table 2: Location of protocols and experimental details in Leslimar Rios-Colon’s 
laboratory notebooks. 
Protocol Notebook # Page(s) 
Protein assay 1 20 
Crystal Violet assay 1 52 
Western Blot Procedure 1 9-10 
LEDGF/p75 overexpressing 
clone preparation – set #1 
1 12 
LEDGF/p75 overexpressing 
clone preparation – set #2 
3 
 
4 
62-63, 65-72, 75-81, 83-87, 
95-96 
22,24-25, 31, 54 
DTX-resistant cell lines 
preparation 
3 
4 
5 
87, 90, 100 
52, 54, 65 
23,40, 49 
LEDGF/p75 knockdown 
procedure 
2 7-8, 11 
MTT assay protocol 2 15 
Immunofluorecence and 
slide preparation protocol 
2 24 
Drug dilutions/information 2 29,30 
Colony formation assay 
protocol 
4 61 
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